

HuProt™ Human Proteome Microarray v4.0

—*User Manual*—

Wendy Yap, Tyler Hulett, Shuang Liu, Bradley Moore, Pedro Ramos
Ignacio Pino, Moises Vargas, Shaohui Hu

Last Updated: September 2023

Microarray Type	Functional Protein Microarray
Species	Human
Production technology	Non-contact piezoelectric inkjet
Slide type	Coated glass (PATH®)
Detection method	Fluorescence
Content	Recombinant human & mouse proteins ^a

^a Please refer to the documentation accompanying the microarrays for specific information.

Contents

1 Technology Overview	4
2 Control Spots	5
3 Storage and Handling	6
3.1 Storage	6
3.2 Handling	6
3.3 Additional Materials and Instruments for Assays	6
3.4 Additional Equipment for Data Analysis	6
4 Data Processing and Analysis	
Resources	6
4.1 Raw Data Extraction From the .gal File	6
4.2 Initial Data Processing From the .gpr Files	6
4.3 Additional Content and Analysis Resources	7
5 General Protocol	7
5.1 General Reagents	7
5.2 General Recipes	7
5.3 Sample Preparation:	8
5.3.1 Serum (or Plasma) Sample Preparation	8
5.3.2 Antibody Specificity Sample Preparation	8
5.3.3 Biotinylated Protein Sample Preparation	8
5.3.4 Biotinylated Small Molecule Sample Preparation	8
5.4 HuProt™ Microarray Preparation	8
5.5 Block the HuProt™ Microarrays	8
5.6 Add the Samples to the HuProt™ Microarrays	9
5.7 First Washing Stage	9
5.8 Add Secondary Antibody (or Streptavidin)	9
5.9 Second Washing Stage	10
5.10 Microarray Drying Stage	10
5.11 Microarray Scanning	10
6 RNA Binding Assays	11
6.1 Reagents for RNA Binding	11
6.2 Recipes for RNA Binding	11
6.3 HuProt™ Microarray Storage and Preparations	11
6.4 Block the HuProt™ Microarrays	11
6.5 RNA Sample Preparation	11
6.6 Add the RNA Samples to the HuProt™ Microarrays	12
6.7 Washing Stage	12
6.8 Microarray Drying Stage	12
6.9 Microarray Scanning	13
6.10 Appendix for RNA Binding Assay	13
7 DNA Binding Assays	13
7.1 Reagents for DNA Binding	13
7.2 Recipes for DNA Binding	13
7.3 HuProt™ Microarray Storage and Preparations	13
7.4 Block the HuProt™ Microarrays	14
7.5 DNA Sample Preparation	14
7.6 Add the Labeled DNA Samples to the HuProt™ Microarrays	14
7.7 Washing Stage	14
7.8 Microarray Drying Stage	14

7.9	Microarray Scanning	15
7.10	Appendix for DNA Binding Assay	15
8	HuProt™ References	16
8.1	Autoantibody Seromics	16
8.2	Antibody Specificity and Crossreactivity	21
8.3	Protein Interactomics	22
8.4	Enzymatic Assays	24
8.5	Nucleic Acid Binding	25
8.6	Small Molecule Profiling	27
8.7	Reviews	28

1 Technology Overview

CDI Labs' HuProt™ Human Proteome Microarray is the most comprehensive human full-length protein array yet created (Jeong et al, 2012). Our latest version, HuProt™ v4.0, contains over 21,000 human proteins and protein isoforms. This covers over 81% of human proteins in each major functional category of the proteome, as defined by the Human Protein Atlas (Venkataraman et al, 2018), and allows hundreds of interactions to be profiled at once in a wide range of applications, including mapping antigen-specific immunity (multi-isotype serum profiling), determining monoclonal antibody specificity, and facilitating studies of protein-protein interaction, substrate identification, protein-DNA binding, protein-RNA binding, and the binding of some small molecules.




Figure by Tyler Hulett, PhD for CDI Antygen; created with BioRender.

The HuProt™ expression library was created by inserting full-length human open reading frames (ORFs) into a yeast high-copy expression vector that produces GST-His6 fusion proteins when induced in yeast (Hu S et al 2009; Jeong J et al 2012).

Each human ORF expression vector was verified for integrity by Sanger sequencing (Venkataraman et al, 2018). These sequence-verified expression vectors encoding human ORFs were transformed into yeast to create our master library; this eukaryotic expression system ensures that HuProt™ proteins maintain both function and proper conformation (Hu S, poster at https://cdi.bio/wp-content/uploads/2019/11/CDI_Well_Folded_Protein_Poster.pdf).

As required — about once per year — this yeast library is used to synthesize human proteins in high-throughput. Full-length synthesized proteins are purified via their GST-His6 fusion tags as previously described (Hu S et al, 2009). These proteins are then frozen in aliquots in a 384-well format for later use in printing on HuProt™ microarrays.

To print individual batches of HuProt™ arrays, the purified human proteins are then printed as duplicate spot pairs using an Arrayjet UltraMarathon printer (Arrayjet, UK) on PATH nitrocellulose slides (GraceBio, USA). Controls on HuProt™ include titrated GST protein, titrated human IgG, other human antibody isotypes, histones, mouse and rabbit anti-biotin, mouse IgM, and biotin-tagged control for streptavidin detection. HuProt™ also contains landmark control spots, including Alex Fluor 555/647 (Jeong et al, 2012). Success of each batch of HuProt™ microarrays is validated by anti-GST staining. This confirms that full-length GST-His6 fusion proteins were successfully expressed, synthesized, purified, and printed across our clone collection.

2 Control Spots

Control	Function
H1 - Histone H1 H2 (A+B) - Histone H2A and H2B mixture H3 - Histone H3 H4 - Histone H4	The histones are non-specific binding proteins used as positive controls for various assays, including serum profiling, antibody specificity assay, protein, DNA, RNA binding assays, etc.
IgG488/594	Alexa Fluor 488/594 labeled IgG, positive control and landmarks for fluorescence detection in 488/594 channels.
Rhodamine + IgG 647	Rhodamine + Alexa Fluor 647 labeled IgG, a positive control and landmarks for fluorescence detection in 532/635 channels.
Anti-human IgA	A positive control for human serum/plasma IgA profiling.
Mouse-anti-biotin	Detects biotin labeled protein probes and serves as a control for anti-mouse antibody detection reagent.
Rabbit-anti-biotin	Detects biotin labeled protein probes and serves as a control for anti-rabbit antibody detection reagent.
BSA - Bovine serum albumin	A negative control for non-specific protein interactions.
Biotin-BSA - biotinylated BSA	A positive control for interaction with streptavidin labeled detection reagent.
Mouse IgM	Positive control for anti-mouse IgM detection.
RanBP2deltaFG	E3 SUMO-Protein Ligase, a positive control for the SUMOylation assay.
hMDM2	E3 Ubiquitin Protein Ligase, a positive control for the ubiquitylation assay.
Er α	Estrogen receptor alpha. A positive control for ligand binding assays.
Human IgM	A positive control for human serum/plasma IgM profiling.
Human IgG 1.5625 ng/ μ L Human IgG 6.25 ng/ μ L Human IgG 25 ng/ μ L Human IgG 100 ng/ μ L	The human IgG gradient serves as a positive control for human serum/plasma IgG profiling and is used for Robust-Linear-Model Normalization in data analysis.
Anti-Human IgG 1.5625 ng/ μ L Anti-Human IgG 6.25 ng/ μ L Anti-Human IgG 25 ng/ μ L Anti-Human IgG 100 ng/ μ L	The Anti-human IgG gradient serves as a positive control for human serum/plasma IgG profiling and is used for Robust-Linear-Model Normalization in data analysis.
GST (glutathione S-transferase) 10 ng/ μ L GST (glutathione S-transferase) 50 ng/ μ L GST (glutathione S-transferase) 100 ng/ μ L GST (glutathione S-transferase) 200 ng/ μ L	The glutathione S-transferase (GST) protein gradient serves as a negative control and is used for background and statistical significance calculations.
Buffer	Printing buffer only, negative control.

NOTE: The active surface of the HuProt™ microarray is also the barcoded side. The microarrays should only be handled at the barcoded end of the microarray. Wear gloves and use tweezers to handle the microarrays.

3 Storage and Handling

3.1 Storage

HuProt™ microarrays are shipped in closed plastic slide holders on dry ice. Please store the microarrays at -80°C immediately upon receipt; be sure to keep the slide holders closed. Each provided holder contains up to x5 HuProt™ arrays.

3.2 Handling

- Always wear gloves
- Do not touch the active surface of the microarray that the proteins are printed on. This is the same surface with the barcode; the barcode also marks the end of the microarray.
- When handling, use tweezers to handle the barcoded end of the microarray.
- The active surface of the microarray must always face up during assays and rinses.
- Do not let the microarray dry out at any time during the procedures.

3.3 Additional Materials and Instruments for Assays

Aluminum foil
Cleanroom wipes (preferred) or paper towels
Micropipettes
Orbital shaker
Sterile disposable micropipette tips
Sterile serological pipettes (25 mL)
Fine-nosed tweezers
Vacuum system
Plastic rectangular 4-well plates with lids (e.g. Thermo Scientific™ Nunc™ Dishes, Rectangular 4-Well, No.12-565-495)
Lightproof Microscope Slide Box
1000mL or 250mL Filter Units (PES membrane, 0.45 µm)
1000mL or 250mL Receiver Units
15.0 mL plastic screw-top tubes
Micropipette tips
Nitrile gloves
Compressed air duster

3.4 Additional Equipment for Data Analysis

Microarray scanner (e.g. Molecular Devices GenePix 4000B)
Microarray data analysis program (e.g. GenePix Pro 6.1)

4 Data Processing and Analysis Resources

4.1 Raw Data Extraction From the .gal File

After scanning, HuProt™ microarrays must be aligned to a file of the array layout (.gal), in order to extract the raw microarray data (.gpr). The most up to date .gal file (ie: HuProt_v4.0_Standard_Gal_Updated_01212022.gal) is always available on this webpage:

<https://collection.cdi-lab.com/public/downloads>

The above .gal file works with common microarray scanning systems such as Molecular Devices Genepix and Innopsys Innoscan Mapix. Please confirm with your microarray scanner manufacturer that HuProt™ is compatible with your systems. More information on .gal files (genepix layout), and .gpr (genepix results) can be found on the Molecular Devices website:

<https://support.moleculardevices.com/s/article/GenePix-File-Formats>

4.2 Initial Data Processing From the .gpr Files

A variety of online tools and resources exist to support microarray data extraction, normalization, and analysis from .gpr files (ie Limma, PAWER, etc). However, not all of the tools and features of these programs are necessarily helpful or appropriate for protein microarray analysis. As yet, there is no scholarly consensus on 'the best way' to analyze HuProt™ data, primarily due to the versatility and variety of studies and assays which can be done with protein microarrays. Different assays and study goals require variation in hit extraction, raw data normalization, etc.

Spots labeled ND (no data) did not pass our collection sequencing processing QC steps as reported (Venkataraman et al. 2018); corrected versions are printed elsewhere on the array. Every protein is printed 'as-purified' and varies in concentration. Parent protein aliquots are known to range from 0.001-2.5 mg/mL in concentration, with an average of 0.15 mg/mL. Each protein aliquot is printed in duplicate with 100 picoliters (pL) volume per protein spot.

In order to support you in processing your .gpr files, a simple script is available here to process a folder of .gpr files into 'stitched output tables:'

<https://github.com/cdi-lab/StarterKit>

The above is a set of simple R scripts for basic, stand-

alone analysis of HuProt™ (gpr) result files. Our data processing StarterKit uses foreground median fluorescence intensity values from each spot pair and averages them; it then outputs a 'raw' and 'quantile normalized' set of files.

IMPORTANT: We do not recommend subtracting the spot-specific background as this is typically both very low on properly stained arrays and can contain 'real signal' from the array spot itself. The nitrocellulose surface most HuProt™ arrays are printed on has a limited protein absorbance capacity, and higher concentration spots will often bleed over and result in 'real signals' in the background halo captured around each spot by GenePix and Mapix software.

4.3 Additional Content and Analysis Resources

The most up to date files related to HuProt™ content and data analysis are always available at this website. File names will be as below, or similar:

<https://collection.cdi-lab.com/public/downloads>

HuProt_V4.0.zip: This contains the complete amino acid sequence of every protein in the HuProt™ collection. The HuProt™ v4.0 zip file includes these columns: system ID, symbol, nucleotide, protein, reviewed UniProt, un-reviewed UnProt, CCDS, RefSeq, Ensembl, synonyms, categories.

230414_-HuProt_HPA_Alignment.xlsx: This contains the Human Protein Atlas alignment with HuProt™ and is used for ontology enrichment analysis, subcellular localization information, etc. The nomenclature alignment is done using a new BLAST results file (230414 - HuProt BLAST Nomenclature.xlsx).

230414_-HuProt_BLAST_Nomenclature_.xlsx: This contains the HuProt™ Sequence BLAST Label Curation versus UniProt (Human and Mouse). No sequences are altered; only the gene symbols are updated.

5 General Protocol

This protocol uses CDIArrayBlock™ and/or Seromics™ Sample Buffer which are included with each HuProt™ v4.0 microarray kit. The following general protocol is used for the assays of:

- **Serum (or plasma) samples**
- **Antibody samples**
- **Biotinylated protein samples**
- **Biotinylated small molecules**

IMPORTANT: Sample handling and dilution descriptions are modular; the core assay is identical across these sample types.

If you have questions about testing non-biotinylated proteins and small molecules, please contact info@cdi.bio.

5.1 General Reagents

Bovine Serum Albumin (IgG-Free, Protease-Free) (e.g. Jackson ImmunoResearch Laboratories 001-000-173)
10X TBS (Tris buffered saline)
Tween® 20
ddH2O

5.2 General Recipes

• **1X TBS-T Buffer (also used as a Washing Buffer):** TBS pH 7.4, 0.1% Tween™ 20. Commercially available 10X TBS may also be purchased. Store the buffer at room temperature.

• **Detection Buffer:** 5% BSA in 1X TBS-T. Filter the solution using a 0.45 µm filtration system, and store at 4 °C until use.

IMPORTANT: Two tubes of buffer are included with the HuProt v4.0 microarrays. **Do not use these buffers if you are testing DNA or RNA binding on HuProt™ microarrays.** Please refer to the CDI User Manual for the relevant protocols for testing nucleic acids.

CDIArrayBlock™ (provided by CDI Labs in 3.0 mL aliquots; store at 4 °C). This can be used for serum, antibody, protein, and small molecule samples.

Seromics™ Sample Buffer (provided by CDI Labs in 3.0 mL aliquots; store at 4 °C; **for serum/plasma samples only**)

5.3 Sample Preparation:

Prepare your samples of interest according to their type below.

5.3.1 Serum (or Plasma) Sample Preparation

1. Thaw the frozen serum (or plasma) samples and place on ice.
2. Remove the tubes of CDIArrayBlock™ and Seromics™ Sample Buffer from storage at 4 °C and place on ice (one tube of each buffer is needed for each HuProt™ microarray).
3. Label the Seromics™ Sample Buffer tubes with the sample names.
4. Add 3.0 µL of neat serum (or plasma) to the Seromics™ Sample Buffer and invert to mix.
5. Incubate at room temperature for 1 hour with gentle shaking. This incubation step can be done when the HuProt™ microarrays are being blocked (section 5.5).

5.3.2 Antibody Specificity Sample Preparation

1. Remove the tubes of CDIArrayBlock™ buffer from storage at 4 °C and place on ice (one tube of the buffer is needed for each HuProt™ microarray).
2. Thaw the monoclonal or polyclonal antibody samples and place on ice until ready to use. Each array uses 3 µg of antibody. The recommended antibody stock concentration is at least 0.1 mg/mL.

5.3.3 Biotinylated Protein Sample Preparation

1. Remove the tubes of CDIArrayBlock™ buffer from storage at 4 °C and place on ice (one tube of the buffer is needed for each HuProt™ microarray).
2. Thaw the biotinylated protein samples and store on ice until ready to use. Each array uses 3 µg of protein sample. The recommended protein stock concentration is at least 0.1 mg/mL.

If you have question about protein samples with other labels, please contact us at info@cdi-lab.com.

5.3.4 Biotinylated Small Molecule Sample Preparation

1. Remove the tubes of CDIArrayBlock™ from storage at 4 °C and place on ice (one tube of the buffer is needed for each HuProt™ microarray).
2. Prepare your small molecule samples at a concentration of 1 mM. Each array uses 30 µL of small molecule sample.

5.4 HuProt™ Microarray Preparation

1. Set aside the exact number of rectangular 4-well plates needed and label them with a permanent marker.
2. Remove plastic slide holders containing HuProt™ microarrays from -80 °C storage; keep the plastic slide holders flat on a layer of dry ice until the blocking stage.

IMPORTANT: Purified proteins are printed on the side of the HuProt™ microarray with the barcode to create the “active surface.” The barcode marks the end of the microarray.

IMPORTANT: Keep the HuProt™ microarrays ultra cold/ultra dry before blocking. Do not let condensation form on the microarray surface.

5.5 Block the HuProt™ Microarrays

1. Use a pipette to add 3.0 mL of CDIArrayBlock™ buffer to each well in the rectangular 4-well plates. Each well will hold one HuProt™ microarray for the assays and subsequent steps.

NOTE: Some users leave an unused, empty well in between each microarray to minimize cross contamination.

2. After all the wells are filled with CDIArrayBlock™ buffer, remove the plastic slide holders containing the HuProt™ arrays from the -80°C freezer, and place the holders flat on a layer of dry ice. The barcodes on the microarrays should be facing up.

3. Carefully remove one HuProt™ microarray from a plastic slide holder with fine-nosed tweezers, holding on to the side with the barcode.

NOTE: The active surface of the HuProt™ microarray is also the barcoded side. The microarrays should be handled only at the barcoded end. Wear gloves and use tweezers to handle the microarrays.

4. Immediately, submerge the microarray in one well of the 4-well plate with the CDIArrayBlock™ buffer, with the active/barcoded side facing up.
5. When all four microarrays have been added to the 4-well plate, gently move the dish in a circular fashion until the blocking solution covers the entire surface of each array.
6. Incubate the arrays at room temperature for 1.0 hr. with gentle shaking (20-40 rpm).

5.6 Add the Samples to the HuProt™ Microarrays

1. **A. For antibodies, biotinylated proteins or small molecules:** Add 3 µg of each antibody or protein sample, or 30 µL of 1 mM small molecule sample to each well of the rectangular 4-well plates containing the HuProt™ arrays that are covered by CDIArrayBlock™ buffer.

Add the samples onto the barcoded area of the blocked HuProt™ microarray (barcode facing up). Do not let the pipette tip touch the microarray surface.

B. For serum/plasma samples:

Carefully decant the liquid from the 4-well plate. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.

Then carefully pipette 3.0 mL of the prepared sample, diluted in Seromics™ Sample Buffer, from the tube onto the barcoded area of the blocked HuProt™ microarray (barcode facing up). Do not let the pipette tip touch the microarray surface.

2. Replace the plastic cover on the 4-well plate when all the test samples have been added.
3. Place the 4-well plates on an orbital shaker, and incubate at room temperature for 1 hour with gentle constant shaking (20-40 rpm). The covered 4-well plates may be stacked for this step.

4. If fluorescently labelled samples are being assayed, be sure to cover the 4-well plates with aluminum foil to minimize light exposure.

5.7 First Washing Stage

1. Following incubation, remove the cover from one of the rectangular 4-well plates.
2. Carefully decant the liquid from the 4-well plate into a designated waste container. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.
3. **RINSING:** Slowly add 4.0 ml of 1X TBS-T solution to each well of the 4-well dish. Make sure to add the solution to the base of the array (over the barcoded area). Quickly rinse the microarray for 5 seconds. Decant the liquid from the 4-well plate into the designated liquid waste container. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.
4. **WASHING:** Slowly refill each well with 4.0mL of 1X TBS-T solution. Make sure to add the solution at the base of the array (over the barcoded area). Place the 4-well plates on an orbital shaker and incubate at room temperature for 10 min with constant shaking (20-40 rpm). Decant the liquid from the 4-well plate into the designated liquid waste container. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.

NOTE: Always make sure that the wells are not left empty, or the microarrays will dry out. Repeat the steps for each rectangular 4-well dish.

5. Repeat for a total of three 10 min washes in 1X TBS-T.

5.8 Add Secondary Antibody (or Streptavidin)

IMPORTANT: For the following steps, cover the 4-well plates containing the HuProt™ microarrays tightly with aluminum foil to minimize light exposure.

IMPORTANT: Prepare the secondary antibody or streptavidin solution (3.5 mL per microarray) immediately before use.

1. Dilute the secondary antibody (for serum or antibody samples) or streptavidin (for biotinylated samples) in the Detection Buffer per manufacturer's directions for Western Blot use. Wrap the containers in aluminum foil.

2. Decant the liquid (TBS-T) covering the washed HuProt™ microarrays from the 4-well plate into a designated liquid waste container. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.
3. Add 3.0 mL of the prepared secondary antibody solution to each HuProt™ microarray. Replace the cover on the 4-well plate after all the wells are filled.
4. Stack the rectangular 4-well plates and cover with foil to block light, or cover the individual 4-well plates with aluminum foil.
5. Place the covered 4-well plates on an orbital shaker. Shake gently (20-30 rpm) for 1.0 hr. at room temperature.

5.9 Second Washing Stage


1. Carefully decant the buffer containing the secondary antibody from the 4-well plate into a designated liquid waste container. The HuProt™ microarrays will stay attached to the bottom of the 4-well plate.
2. TBS-T RINSE: Slowly add 4.0ml 1X TBS-T over the barcoded end of the microarray, and briefly rinse the microarray for 5.0 seconds. Carefully decant the rinse buffer.
3. TBS-T WASHES: Slowly add 4.0 ml of 1X TBS-T over the barcoded end of the microarray and incubate for 10 min at room temperature with gentle shaking on an orbital shaker (20-30 rpm).
4. Carefully decant the wash buffer from the 4-well plate into a designated liquid waste container.
5. Repeat for a total of three 10 min washes in 1X TBS-T.
6. ddH2O RINSES: Carefully add 4.0 mL of ddH2O to the barcoded end of each microarray. Rinse for 5 seconds. Then carefully decant the ddH2O into a designated liquid waste container.
7. Repeat for a total of three rinses in ddH2O.
8. Leave the microarray in ddH2O after the third rinse and immediately proceed to the drying stage.

IMPORTANT: Go to the drying stage immediately.

5.10 Microarray Drying Stage

1. Label a light-proof microscope slide box to store the microarrays.

2. Carefully use tweezers to remove one HuProt™ microarray (submerged in ddH2O) from the 4-well plate, by holding on to the barcoded area. Do not remove more than one microarray at a time.
3. Gently tap a corner of the microarray on a clean room wipe to wick away excess water.



4. Gently blow the microarray dry from the barcoded area, using a constant angled flow of compressed air.
5. Gently tap the edges and back of the microarray on a clean room wipe to wick away excess water.
6. Place each dried microarray inside the light-proof microscope slide box.
7. Store the microarrays in the order in which they were processed.
8. Once all the HuProt™ microarrays are dried and stored, immediately proceed to the scanning step.
9. Alternatively, store the light-proof slide box at 4°C overnight, and scan the microarrays the next day.

5.11 Microarray Scanning

1. The HuProt™ microarray should be scanned immediately after drying (highly preferable), or stored at 4°C in a lightproof microscope box overnight.
2. If the microarrays are stored overnight at 4°C, they must be scanned the next day. Place the covered lightproof microscope box containing the microarrays on a bench at room temperature for 30 minutes, to bring the arrays to room temperature before scanning.

6 RNA Binding Assays

IMPORTANT: Do not use the CDIArrayBlock™ or Seromics™ Sample Buffer for RNA binding assays.

The RNA samples should be fluorescently labeled.

6.1 Reagents for RNA Binding

Bovine Serum Albumin (IgG-Free, Protease-Free) (e.g. Jackson ImmunoResearch Laboratories 001-000-173)
10X TBS (Tris buffered saline)

Tween® 20

ssDNA (herring sperm)

MgCl₂

SuperBlockT20 (PBS) Blocking Buffer (Thermo Scientific Cat. No. 37516)

DEPC-treated water

PBS

6.2 Recipes for RNA Binding

•**RNA Binding Assay Blocking Buffer:** 10 µg/mL ssDNA (herring sperm), 2 mM MgCl₂, 5 mg/mL BSA in SuperBlock T20 (PBS) Blocking Buffer

•**RNA Binding Buffer:** 2 mM MgCl₂; 2 mg/mL BSA (filtered with a 0.45 µm filtration system), 10 µg/mL ssDNA (herring sperm) in 1X PBS

•**Washing Buffer:** 1X TBS pH 7.4, 0.1% Tween™ 20. Commercially available 10X TBS may also be purchased. Store the buffer at room temperature.

6.3 HuProt™ Microarray Storage and Preparations

NOTE: Purified proteins are printed on the side of the HuProt™ microarray with the barcode to create the “active surface.” The barcode marks the end of the microarray.

1. Prepare the blocking and binding buffers and store on ice or at 4°C. Prepare the washing buffer.
2. Set aside the exact number of rectangular 4-well plates needed and label them with a permanent marker.
3. Store HuProt™ microarrays in closed plastic slide holders at -80 °C (each holder holds up to 5 HuProt™ arrays).
4. After removing plastic slide holders containing microarrays from -80 °C storage, place the plastic slide

holders flat on a layer of dry ice, until the blocking stage.

IMPORTANT: Keep the HuProt™ microarrays ultra cold/ultra dry before blocking. Do not let condensation form on the microarray surface.

6.4 Block the HuProt™ Microarrays

1. Use a serological pipette to add 3.0 mL of RNA Binding Assay Blocking Buffer to each well in the rectangular 4-well plates. Each well will hold one HuProt™ microarray for the assays and subsequent steps.
- NOTE: Some users leave an unused, empty well in between each microarray to minimize cross contamination.
2. After the wells are filled with RNA Binding Assay Blocking Buffer, remove the plastic slide holders containing the HuProt™ arrays from the -80 °C freezer, and place the holders flat on a layer of dry ice. The barcodes on the microarrays should be facing up.
3. Carefully remove one HuProt™ microarray from a plastic slide holder with fine-nosed tweezers, holding on to the side with the barcode.

NOTE: The active surface of the HuProt™ microarray is also the barcoded side. The microarrays should be handled only at the barcoded end. Wear gloves and use tweezers to handle the microarrays.

4. Immediately, submerge the microarray in one well of the 4-well plate with the blocking buffer, with the active/barcoded side facing up.
5. When all four microarrays have been added to the 4-well plate, gently move the dish in a circular fashion until the blocking solution covers the entire surface of each array.
6. Incubate the arrays at room temperature for 1 hr. with gentle shaking (20-40 rpm).

6.5 RNA Sample Preparation

1. Dilute the fluorescently labeled RNA sample to a concentration of 250 nM in 3.0 ml of RNA binding buffer (store the RNA binding buffer on ice or at 4 °C until ready to use; use aluminum foil to minimize light exposure once the RNA sample has been added). For all subsequent assay steps conducted in 4-well plates, cover the plates with aluminum foil to minimize light exposure.

6.6 Add the RNA Samples to the HuProt™ Microarrays

1. Carefully decant the liquid from the 4-well plate. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.
2. Carefully pipette 3.0 mL of the prepared RNA sample (diluted in RNA binding buffer) onto the barcoded area of the blocked HuProt™ microarray (barcode facing up). Do not let the pipette tip touch the microarray surface.
3. Replace the plastic cover on the 4-well plate when all the test samples have been added. Cover the 4-well plates with aluminum foil to minimize exposure to light.
4. Place the 4-well plates on an orbital shaker, and incubate at room temperature for 1 hour with gentle constant shaking (20-40 rpm). The 4-well plates may be stacked and then covered with foil for this step.

6.7 Washing Stage

1. Following incubation, remove the cover from one of the rectangular 4-well plates.
2. Carefully decant the liquid from the 4-well plate into a designated waste container. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.
3. RINSING: Slowly add 4.0 mL of 1X TBS-T solution to each well of the 4-well dish. Make sure to add the solution to the base of the array (over the barcoded area). Quickly rinse the microarray for 5 seconds. Decant the liquid from the 4-well plate into a designated waste container. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.
4. WASHING: Slowly refill each well with 4.0 mL of 1X TBS-T solution. Make sure to add the solution at the base of the array (over the barcoded area). Cover the 4-well plates with foil and then place on an orbital shaker and incubate at room temperature for 10 min with constant shaking (20-40 rpm). Decant the liquid from the 4-well plate into a designated waste container. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.


NOTE: Always make sure that the wells are not left empty, or the microarrays will dry out. Repeat the steps for each rectangular 4-well dish. Be sure to cover the 4-well plates with aluminum foil at all times to minimize light exposure.

5. Repeat for a total of three 10 min washes in 1X TBS-T.
6. FINAL RINSES: Carefully add 4.0 mL of DEPC-treated water to the barcoded end of each microarray. Rinse for 5 seconds. Then carefully decant the water into a designated liquid waste container.
7. Repeat for a total of three rinses in DEPC-treated water.
8. Leave the microarray in DEPC-treated water after the third rinse and immediately proceed to the drying step.

IMPORTANT: Go to the drying stage immediately.

6.8 Microarray Drying Stage

1. Label a light-proof microscope slide box to store the microarrays.
2. Carefully use tweezers to remove one HuProt™ microarray (submerged in DEPC-treated water) from the 4-well plate, by holding on to the barcoded area. Do not remove more than one microarray at a time.
3. Gently tap a corner of the microarray on a clean room wipe to wick away excess water.



4. Gently blow the microarray dry from the barcoded area, using a constant angled flow of compressed air.
5. Gently tap the edges and back of the microarray on a clean room wipe to wick away excess water.

- Place each dried microarray inside the light-proof microscope slide box.
- Store the microarrays in the order in which they were processed.
- Once all the HuProt™ microarrays are dried and stored, immediately proceed to the scanning step.
- Alternatively, store the light-proof slide box at 4 °C overnight, and scan the microarrays the next day.

6.9 Microarray Scanning

- The HuProt™ microarray should be scanned immediately after drying (highly preferable), or stored at 4 °C in a lightproof microscope box overnight.
- If the microarrays are stored overnight, they must be scanned the next day. Rest the lightproof microscope box containing the microarrays on a bench at room temperature for 30 min to bring the arrays to room temperature before scanning.

6.10 Appendix for RNA Binding Assay

Two tubes of buffer, CDIArrayBlock™ and Seromics™ Sample Buffer, are included with each HuProt v4.0 microarray purchased. Do not use these two buffers for RNA binding assays on HuProt™ microarrays. Please refer to the relevant protocols and recipes shown at the beginning of this protocol (Section 6).

7 DNA Binding Assays

IMPORTANT: Do not use CDIArrayBlock™ or Seromics™ Sample Buffer for DNA binding assays.

The DNA samples should be fluorescently labeled.

7.1 Reagents for DNA Binding

ddH₂O
HEPES
Potassium glutamate
DTT
Glycerol
Poly (dA-dT)

7.2 Recipes for DNA Binding

DNA Hybridization Buffer: 25 mM HEPES at pH 8.0; 50 mM potassium glutamate; 0.1% Triton X-100; 8 mM magnesium acetate; 3 mM DTT (freshly made, and added to the buffer right before use); 4 μM poly (dA-dT); 10% glycerol. Store on ice or at 4 °C.

Washing Buffer: Same as above, but without poly (dA-dT). Store on ice or at 4 °C.

7.3 HuProt™ Microarray Storage and Preparations

NOTE: Purified proteins are printed on the side of the HuProt™ microarray with the barcode to create the “active surface.” The barcode marks the end of the microarray.

- Prepare the DNA Hybridization Buffer and store on ice. Prepare the washing buffer.
- Set aside the exact number of rectangular 4-well plates needed and label them with a permanent marker.
- Store HuProt™ microarrays in closed plastic slide holders at -80 °C (each holder holds up to 5 HuProt™ arrays).
- After removing plastic slide holders containing microarrays from -80 °C storage, place the plastic slide holders flat on a layer of dry ice, until the blocking stage.

IMPORTANT: Keep the HuProt™ microarrays ultra cold/ultra dry before blocking. Do not let condensation form on the microarray surface.

7.4 Block the HuProt™ Microarrays

1. Use a serological pipette to add 3.0 ml of DNA Hybridization Buffer (pre-chilled and stored at 4 °C) to each well in the rectangular 4-well plates. Each well will hold one HuProt™ microarray for the assays and subsequent steps.

NOTE: Some users leave an unused, empty well in between each microarray to minimize cross contamination.

2. After all the wells are filled with DNA Hybridization Buffer, remove the plastic slide holders containing the HuProt™ arrays from the -80 °C freezer, and place the holders flat on a layer of dry ice. The barcodes on the microarrays should be facing up.
3. Carefully remove one HuProt™ microarray from a plastic slide holder with fine-nosed tweezers, holding on to the side with the barcode.

NOTE: The active surface of the HuProt™ microarray is also the barcoded side. The microarrays should be handled only at the barcoded end. Wear gloves and use tweezers to handle the microarrays.

4. Immediately, submerge the microarray in one well of the 4-well plate with the DNA Hybridization Buffer, with the active/barcoded side facing up.
5. When all four microarrays have been added to the 4-well plate, gently move the dish in a circular fashion until the blocking solution covers the entire surface of each array.
6. Incubate the arrays at 4 °C for 3 hours with gentle shaking (20-40 rpm).

7.5 DNA Sample Preparation

1. Dilute the fluorescently labeled DNA sample to a concentration of 40 nM in 3.0 ml of DNA hybridization buffer containing poly (dA-dT) and store on ice until use. (use aluminum foil to minimize light exposure once the DNA sample has been added to the buffer). For subsequent assay steps conducted in 4-well plates, cover the plates with aluminum foil to minimize light exposure.

7.6 Add the Labeled DNA Samples to the HuProt™ Microarrays

1. Carefully decant the liquid from the 4-well plate. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.

2. Carefully pipette 3.0 mL of the prepared DNA sample (diluted in DNA binding buffer) onto the bar-coded area of the blocked HuProt™ microarray (barcode facing up). Do not let the pipette tip touch the microarray surface.
3. Replace the plastic cover on the 4-well plate when all the test samples have been added. Cover the 4-well plates with aluminum foil to minimize exposure to light.
4. Place the 4-well plates on an orbital shaker, and incubate at 4 °C overnight with gentle constant shaking (20-40 rpm). The covered 4-well plates may be stacked and then covered with foil for this step.

7.7 Washing Stage


1. One wash cycle is sufficient for the DNA Binding Assay
2. Following incubation, remove the cover from one of the rectangular 4-well plates.
3. Carefully decant the liquid from the 4-well plate into a designated waste container. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.
4. **WASHING:** Add 4.0 mL of pre-chilled wash buffer (chilled at 4 °C) to each well of the 4-well dish. Make sure to add the solution to the base of the array (over the barcoded area). Incubate with gentle shaking for 1-3 min at 4 °C. Decant the liquid from the 4-well plate into the designated waste container. The HuProt™ microarray will stay attached to the bottom of the 4-well plate.

IMPORTANT: Check that no wells are left empty, or the microarrays will dry out. Repeat the steps for each rectangular 4-well dish. Cover the 4-well plates with aluminum foil at all times to minimize light exposure.

IMPORTANT: Go to the drying stage immediately.

7.8 Microarray Drying Stage

1. Label a light-proof microscope slide box to store the microarrays.
2. Carefully use tweezers to remove one HuProt™ microarray (submerged in wash buffer) from the 4-well plate, by holding on to the barcoded area. Do not remove more than one microarray at a time.



HuProt™ microarrays. Please refer to the relevant protocols and recipes shown at the beginning of this protocol (Section 7).

3. Gently tap a corner of the microarray on a clean room wipe to wick away excess water.
4. Gently blow the microarray dry from the barcoded area, using a constant angled flow of compressed air.
5. Gently tap the edges and back of the microarray on a clean room wipe to wick away excess water.
6. Place each dried microarray inside the light-proof microscope slide box.
7. Store the microarrays in the order in which they were processed.
8. Once all the HuProt™ microarrays are dried and stored, immediately proceed to the scanning step.
9. Alternatively, store the light-proof slide box at 4 °C overnight, and scan the microarrays the next day.

7.9 Microarray Scanning

1. The HuProt™ microarrays should be scanned immediately after drying (highly preferable), or stored at 4 °C in a lightproof microscope box overnight.
2. If the microarrays are stored overnight, they must be scanned the next day. Rest the lightproof microscope box containing the microarrays on a bench at room temperature for 30 minutes, to bring the arrays to room temperature before scanning.

7.10 Appendix for DNA Binding Assay

Two tubes of buffer, CDIArrayBlock™ and Seromics™ Sample Buffer, are included with each HuProt™ microarray. Do not use these buffers for DNA binding assays on

8 HuProt™ References

8.1 Autoantibody Seromics

1. L. Zhuang, C. Huang, Z. Ning, L. Yang, W. Zou, P. Wang, C. Cheng, Z. Meng, Circulating tumor-associated autoantibodies as novel diagnostic biomarkers in pancreatic adenocarcinoma, *Intl Journal of Cancer*. 152 (2023) 1013–1024. <https://doi.org/10.1002/ijc.34334>.
2. Q. Yang, H. Ye, G. Sun, K. Wang, L. Dai, C. Qiu, J. Shi, J. Zhu, X. Wang, P. Wang, Human Proteome Microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma, *Molecular Oncology*. 17 (2023) 887–900. <https://doi.org/10.1002/1878-0261.13371>.
3. X. Xie, L. Tian, Y. Zhao, F. Liu, S. Dai, X. Gu, Y. Ye, L. Zhou, X. Liu, Y. Sun, X. Zhao, BACH1-induced ferroptosis drives lymphatic metastasis by repressing the biosynthesis of monounsaturated fatty acids, *Cell Death Dis*. 14 (2023) 48. <https://doi.org/10.1038/s41419-023-05571-z>.
4. Y. Wang, J. Li, X. Zhang, M. Liu, L. Ji, T. Yang, K. Wang, C. Song, P. Wang, H. Ye, J. Shi, L. Dai, Autoantibody signatures discovered by HuProt protein microarray to enhance the diagnosis of lung cancer, *Clinical Immunology*. 246 (2023) 109206. <https://doi.org/10.1016/j.clim.2022.109206>.
5. T.L. Voyer, A. Gervais, J. Rosain, A. Parent, A. Cederholm, D. Rinchai, L. Bizien, G. Hancioglu, Q. Philippot, M.S. Gueye, M.R. Luxman, M. Renkilaraj, M. Ogishi, C. Soudée, M. Migaud, F. Rozenberg, M. Momenilandi, Q. Riller, L. Imberti, O. Delmonte, G. Müller, B. Keller, J. Orrego, W.A. Gallego, T. Rubin, M. Emiroglu, N. Parvaneh, D. Eriksson, M. Aranda-Guillen, D.I. Berrios, L. Vong, C.H. Kataralis, P. Mustillo, J. Rädler, J. Bohlen, J.B. Celik, C. Astudillo, S. Winter, A. Guichard, V. Béziat, J. Bustamante, Q. Pan-Hammarström, Y. Zhang, L.B. Rosen, S.M. Holland, H. Kenney, K. Boztuğ, N. Mahlaoui, S. Latour, R. Abraham, V. Lougaris, F. Hauck, A. Sediva, F. Atschekzei, M.C. Poli, M.A. Slatter, B. Palterer, M.D. Keller, A. Pinzon-Charry, A. Sullivan, L. Droney, D. Suan, N. Aladjidi, M. Hie, E. Lazaro, J. Franco, S. Keles, M. Malphette, M. Pasquet, M.E. Maccari, A. Meinhardt, A. Ikinciogullari, M. Shahrooei, F. Celmeli, P. Frosk, C.C. Goodnow, P.E. Gray, A. Belot, H.S. Kuehn, S.D. Rosenzweig, F. Licciardi, A. Servettaz, V. Barlogis, G.L. Guenno, V.-M. Herrmann, T. Kuijpers, G. Ducoux, F. Sarrot-Reynauld, C. Schuetz, C. Cunningham-Rundles, F. Rieux-Laucat, S.G. Tangye, C. Sobacchi, R. Doffinger, K. Warnatz, B. Grimbacher, C. Fieschi, L. Berteloot, V. Bryant, S.T. Assant, L.D. Notarangelo, H. Su, B. Neven, L. Abel, Q. Zhang, B. Boisson, A. Cobat, E. Jouanguy, O. Kampe, P. Bastard, C. Roifman, N. Landegren, M.S. Anderson, J.-L. Casanova, A. Puel, Impaired thymic AIRE expression underlies autoantibodies against type I IFNs in humans with inborn errors of the alternative NF-κB pathway, *Preprints*, 2023. <https://doi.org/10.22541/au.167330741.18394805/v1>.
6. G.-D. Syu, F.X.R. Sutandy, K. Chen, Y. Cheng, C.-S. Chen, J.C. Shih, Autoantibody profiling of monoamine oxidase A knockout mice, an autism spectrum disorder model, *Brain, Behavior, and Immunity*. 107 (2023) 193–200. <https://doi.org/10.1016/j.bbi.2022.10.001>.
7. E. Shenderov, A.M. De Marzo, T.L. Lotan, H. Wang, S. Chan, S.J. Lim, H. Ji, M.E. Allaf, C. Chapman, P.A. Moore, F. Chen, K. Sorg, A.M. White, S.E. Church, B. Hudson, P.A. Fields, S. Hu, S.R. Denmeade, K.J. Pienta, C.P. Pavlovich, A.E. Ross, C.G. Drake, D.M. Pardoll, E.S. Antonarakis, Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial, *Nat Med*. 29 (2023) 888–897. <https://doi.org/10.1038/s41591-023-02284-w>.
8. F. Moadab, X. Wang, R. Najjar, K.C. Ukadike, S. Hu, T. Hulett, A.A. Bengtsson, C. Lood, T. Mustelin, Argonaute, vault, and ribosomal proteins targeted by autoantibodies in systemic lupus erythematosus, *J Rheumatol*. (2023) jrheum.2022-1327. <https://doi.org/10.3899/jrheum.2022-1327>.
9. B.D. Michael, C. Dunai, E.J. Needham, K. Tharmaratnam, R. Williams, Y. Huang, S.A. Boardman, J. Clark, P. Sharma, K. Subramaniam, G.K. Wood, C. Collie, R. Digby, A. Ren, E. Norton, M. Leibowitz, S. Ebrahimi, A. Fower, H. Fox, E. Tato, M. Ellul, G. Sunderland, M. Held, C. Hetherington, F. Nkongho, A. Palmos, A. Grundmann, J.P. Stewart, M. Griffiths, T. Solomon, G. Breen, A. Coles, J. Cavanagh, S.R. Irani, A. Vincent, L. Taams, D.K. Menon, Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses, *Infectious Diseases (except HIV/AIDS)*, 2023. <https://doi.org/10.1101/2023.04.03.23287902>.
10. C. Mandel-Brehm, S.E. Vazquez, C. Liverman, M. Cheng, Z. Quandt, A.F. Kung, A. Parent, B. Miao, E. Disse, C. Cugnet-Anceau, S. Dalle, E. Orlova, E. Frolova, D. Alba, A. Michels, B.E. Oftedal, M.S. Lionakis, E.S. Husebye, A.K. Agarwal, X. Li, C. Zhu, Q. Li, E. Oral, R. Brown, M.S. Anderson, A. Garg, J.L. DeRisi, Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy,

- Diabetes. 72 (2023) 59–70.
<https://doi.org/10.2337/db21-1172>.
11. L. Malle, R.S. Patel, M. Martin-Fernandez, O.J. Stewart, Q. Philippot, S. Buta, A. Richardson, V. Barcessat, J. Taft, P. Bastard, J. Samuels, C. Mircher, A.-S. Rebillat, L. Maillebouis, M. Vilaire-Meunier, K. Tuballes, B.R. Rosenberg, R. Trachtman, J.-L. Casanova, L.D. Notarangelo, S. Gnjjatic, D. Bush, D. Bogunovic, Autoimmunity in Down's syndrome via cytokines, CD4 T cells and CD11c+ B cells, *Nature*. 615 (2023) 305–314.
<https://doi.org/10.1038/s41586-023-05736-y>.
 12. N. Lou, C. Zheng, Y. Wang, C. Liang, Q. Tan, R. Luo, L. Zhang, T. Xie, Y. Shi, X. Han, Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays, *Cancer Immunol Immunother*. 72 (2023) 235–247.
<https://doi.org/10.1007/s00262-022-03242-0>.
 13. P. Laudański, G. Rogalska, D. Warzecha, M. Lipa, G. Mańka, M. Kiecka, R. Spaczyński, P. Piekarski, B. Banaszewska, A. Jakimiuk, T. Issat, W. Rokita, J. Młodawski, M. Szubert, P. Sieroszewski, G. Raba, K. Szczupak, T. Kluz, M. Kluza, T. Neuman, P. Adler, H. Peterson, A. Salumets, M. Wielgos, Autoantibody screening of plasma and peritoneal fluid of patients with endometriosis, *Human Reproduction*. 38 (2023) 629–643.
<https://doi.org/10.1093/humrep/dead011>.
 14. X. Feng, W. Tong, J. Li, Y. Xu, S. Zhu, W. Xu, Diagnostic value of anti-Kaiso autoantibody in axial spondyloarthritis, *Front. Immunol*. 14 (2023) 1156350.
<https://doi.org/10.3389/fimmu.2023.1156350>.
 15. A. Barpanda, C. Tuckley, A. Ray, A. Banerjee, S.P. Duttagupta, C. Kantharia, S. Srivastava, A protein microarray-based serum proteomic investigation reveals distinct autoantibody signature in colorectal cancer, *Proteomics Clinical Apps*. 17 (2023) 2200062.
<https://doi.org/10.1002/prca.202200062>.
 16. C. Auger, H. Moudgalya, M.R. Neely, J.T. Stephan, I. Tarhoni, D. Gerard, S. Basu, C.L. Fhied, A. Abdelkader, M. Vargas, S. Hu, T. Hulett, M.J. Liptay, P. Shah, C.W. Seder, J.A. Borgia, Development of a Novel Circulating Autoantibody Biomarker Panel for the Identification of Patients with 'Actionable' Pulmonary Nodules, *Cancers*. 15 (2023) 2259.
<https://doi.org/10.3390/cancers15082259>.
 17. C. Auger, H. Moudgalya, P. Shah, M. Liptay, C. Seder, J. Borgia, PP01.33 Serum Autoantibodies may help Identify Individuals with Actionable Pulmonary Nodules on LDCT Scan, *Journal of Thoracic Oncology*. 18 (2023) e24.
<https://doi.org/10.1016/j.jtho.2022.09.059>.
 18. A.R. Ahmadi, G. Song, T. Gao, J. Ma, X. Han, M. Hu, A.M. Cameron, R. Wesson, B. Philosophe, S. Ottmann, E.A. King, A. Gurakar, L. Qi, B. Peiffer, J. Burdick, R.A. Anders, Z. Zhou, D. Feng, H. Lu, C.-S. Chen, J. Qian, B. Gao, H. Zhu, Z. Sun, Discovery and characterization of cross-reactive intrahepatic antibodies in severe alcoholic hepatitis, *Pathology*, 2023.
<https://doi.org/10.1101/2023.02.23.529702>.
 19. J. Wu, P. Wang, Z. Han, T. Li, C. Yi, C. Qiu, Q. Yang, G. Sun, L. Dai, J. Shi, K. Wang, H. Ye, A novel immunodiagnosis panel for hepatocellular carcinoma based on bioinformatics and the autoantibody-antigen system, *Cancer Science*. 113 (2022) 411–422.
<https://doi.org/10.1111/cas.15217>.
 20. S.-M. Shim, Y.H. Koh, J.-H. Kim, J.-P. Jeon, A combination of multiple autoantibodies is associated with the risk of Alzheimer's disease and cognitive impairment, *Sci Rep*. 12 (2022) 1312.
<https://doi.org/10.1038/s41598-021-04556-2>.
 21. K. Sacco, R. Castagnoli, S. Vakkilainen, C. Liu, O.M. Delmonte, C. Oguz, I.M. Kaplan, S. Alehashemi, P.D. Burbelo, F. Bhuyan, A.A. De Jesus, K. Dobbs, L.B. Rosen, A. Cheng, E. Shaw, M.S. Vakkilainen, F. Pala, J. Lack, Y. Zhang, D.L. Fink, V. Oikonomou, A.L. Snow, C.L. Dalgard, J. Chen, B.A. Sellers, G.A. Montealegre Sanchez, K. Barron, E. Rey-Jurado, C. Vial, M.C. Poli, A. Licari, D. Montagna, G.L. Marseglia, F. Licciardi, U. Ramenghi, V. Discepolo, A. Lo Vecchio, A. Guarino, E.M. Eisenstein, L. Imberti, A. Sottini, A. Biondi, S. Mató, D. Gerstbacher, M. Truong, M.A. Stack, M. Magliocco, M. Bosticardo, T. Kawai, J.J. Danielson, T. Hulett, M. Askenazi, S. Hu, NIAID Immune Response to COVID Group, J. Barnett, X. Cheng, K. Kaladi, V. Kuram, J. Mackey, N.M. Bansal, A.J. Martins, B. Palterer, H. Matthews, U. Mudunuri, M. Nambiar, A.J. Oler, A. Rastegar, S. Samuel, C. Shyu, V. Waingankar, S. Weber, S. Xirasagar, Chile MIS-C Group, Y. Espinosa, C. Astudillo, C. Piñera, R. González, Pavia Pediatric COVID-19 Group, M. De Filippo, M. Votto, L. Montagna, J.I. Cohen, H.C. Su, D.B. Kuhns, M.S. Lionakis, T.M. Snyder, S.M. Holland, R. Goldbach-Mansky, J.S. Tsang, L.D. Notarangelo, Immunopathological signatures in multi-system inflammatory syndrome in children and pediatric COVID-19, *Nat Med*. 28 (2022) 1050–1062.
<https://doi.org/10.1038/s41591-022-01724-3>.
 22. E.J. Needham, A.L. Ren, R.J. Digby, E.J. Norton, S. Ebrahimi, J.G. Outtrim, D.A. Chatfield, A.E. Mank-

- telow, M.M. Leibowitz, V.F.J. Newcombe, R. Doffinger, G. Barcenas-Morales, C. Fonseca, M.J. Tausig, R.M. Burnstein, R.J. Samanta, C. Dunai, N. Sithole, N.J. Ashton, H. Zetterberg, M. Gisslén, A. Edén, E. Marklund, P.J.M. Openshaw, J. Dunning, M.J. Griffiths, J. Cavanagh, G. Breen, S.R. Irani, A. Elmer, N. Kingston, C. Summers, J.R. Bradley, L.S. Taams, B.D. Michael, E.T. Bullmore, K.G.C. Smith, P.A. Lyons, A.J. Coles, D.K. Menon, Cambridge NeuroCOVID Group, F. Anwar, K. Allinson, J. Bhatti, E.T. Bullmore, D.A. Chatfield, D. Christmas, A.J. Coles, J.P. Coles, M. Correia, T. Das, P.C. Fletcher, A.W. Jubb, V.C. Lupson, A.E. Manktelow, D.K. Menon, A. Michell, E.J. Needham, V.F.J. Newcombe, J.G. Outtrim, L. Pointon, C.T. Rodgers, J.B. Rowe, C. Rua, N. Sithole, L.R.B. Spindler, E.A. Stamatakis, J. Taylor, F. Valerio, B. Widmer, G.B. Williams, P.F. Chinnery, CITIID-NIHR COVID-19 BioResource Collaboration, J. Allison, G. Alvio, A. Ansari pour, S. Baker, S. Baker, L. Bergamaschi, A. Bermperi, A. Betancourt, H. Biggs, S.-H. Bong, G. Bower, J.R. Bradley, K. Brookes, A. Bucke, B. Bullman, K. Bunclark, H. Butcher, S. Caddy, J. Calder, L. Caller, L. Canna, D. Caputo, M. Chandler, Y. Chaudhry, P. Chinnery, D. Clapham-Riley, D. Cooper, C. Cossetti, C. Crucusio, I. Cruz, M. Curran, J.D. Coudert, E.M.D.D.D. Bie, R.D. Jesus, A.D. Sa, A.-M. Dean, K. Dempsey, E. Dewhurst, G.D. Stefano, J. Domingo, G. Dougan, B.J. Dunmore, A. Elmer, M. Epping, C. Fahey, S. Fawke, T. Feltwell, C. Fernandez, S. Fuller, A. Furlong, I. Georgana, A. George, N. Gleadall, I.G. Goodfellow, S. Gräf, B. Graves, J. Gray, R. Grenfell, R.K. Gupta, G. Hall, W. Hamilton, J. Harris, S. Hein, C. Hess, S. Hewitt, A. Hinch, J. Hodgson, M. Hosmillo, E. Holmes, C. Houldcroft, C. Huang, O. Huhn, K. Hunter, T. Ivers, A. Jahun, S. Jackson, I. Jarvis, E. Jones, H. Jones, S. Jose, M. Josipović, M. Kasanicki, J. Kennet, F. Khokhar, Y. King, N. Kingston, J. Kourampa, E.L. Gresley, E. Laurenti, E. Legchenko, P.J. Lehner, D. Lewis, E. Li, R. Linger, P.A. Lyons, M. Mackay, J.C. Marioni, J. Marsden, J. Martin, C. Matara, N.J. Matheson, C. McMahon, A. Meadows, S. Meloy, V. Mendoza, L. Meredith, N. Mende, F. Mescia, A. Michael, A. Moulton, R. Michel, L. Mwaura, F. Muldoon, F. Nice, C. O'Brien, C. Ocaya, C. O'Donnell, G. Okecha, O. Omarjee, N. Ovington, W.H. Owehand, S. Papadia, R. Paraschiv, S. Parmar, C. Pascuale, C. Patterson, C. Penkett, M. Perales, M. Perera, I. Phelan, M. Pinckert, L. Pointon, P. Polgarova, G. Polwarth, N. Pond, J. Price, V. Ranganath, C. Publico, R. Rastall, C. Ribeiro, N. Richoz, V. Romashova, S. Rossi, J. Rowlands, V. Ruffolo, J. Sambrook, C. Saunders, N.S. Yarkoni, K. Schon, M. Selvan, R. Sharma, J. Shih, K.G.C. Smith, S. Spencer, L. Stefanucci, H. Stark, J. Stephens, K.E. Stirrups, M. Strezlecki, C. Summers, R. Sutcliffe, J.E.D. Thaventhiran, T. Tilly, Z. Tong, H. Tordesillas, C. Treacy, M. Toshner, P. Townsend, C. Treacy, L. Turner, P. Vargas, B. Vergese, J.V. Ziegenweidt, N. Walker, L. Watson, J. Webster, M.P. Weekes, N.K. Wilson, J. Wood, J. Worsley, M. Wylot, A. Yakovleva, C.Y.A.J.-A. Zerrudo, Cambridge NIHR Clinical Research Facility, C. Saunders, A. Elmer, Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses, *Brain*. 145 (2022) 4097–4107. <https://doi.org/10.1093/brain/awac321>.
23. R. Luo, C. Zheng, W. Song, Q. Tan, Y. Shi, X. Han, High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes, *Cancer Science*. 113 (2022) 770–783. <https://doi.org/10.1111/cas.15227>.
 24. D. Kumar, C. Prince, T. Hulett, P. Ramos, O. Candelario, L. Youngblood, M. Briones, C. Bennett, S. Chandrakasan, Pediatric Evans Syndrome Displays Broad Immune Dysregulation Characterized By Extra-Follicular B-Cell Responses and Unique Autoantibody Repertoire, *Blood*. 140 (2022) 1646–1647. <https://doi.org/10.1182/blood-2022-169527>.
 25. P. Johannet, W. Liu, D. Fenyo, M. Wind-Rotolo, M. Krogsgaard, J.M. Mehnert, J.S. Weber, J. Zhong, I. Osman, Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade, *Clinical Cancer Research*. 28 (2022) 4121–4130. <https://doi.org/10.1158/1078-0432.CCR-22-0404>.
 26. A. Gandhi, J. Taylor, M. Morici, A. Reid, T. Meniawy, M.A. Khattak, E. Gray, M. Millward, P. Zaenker, Autoantibodies as potential biomarkers of immune-related adverse events in patients with advanced cutaneous melanoma treated with immune checkpoint inhibitors., *JCO*. 40 (2022) 9536–9536. https://doi.org/10.1200/JCO.2022.40.16_suppl.9536.
 27. W. Fan, X. Fang, C. Hu, G. Fei, Q. Xiao, Y. Li, X. Li, J.D. Wood, X. Zhang, Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray, *Front. Physiol*. 13 (2022) 1010069. <https://doi.org/10.3389/fphys.2022.1010069>.
 28. T.V. Clendenen, S. Hu, Y. Afanasyeva, M. Askenazi, K.L. Koenig, T. Hulett, M. Liu, S. Liu, F. Wu, A. Zeleniuch-Jacquotte, Y. Chen, Temporal reproducibility of IgG and IgM autoantibodies in serum from healthy women, *Sci Rep*. 12 (2022) 6192. <https://doi.org/10.1038/s41598-022-10174-3>.

29. L. Cinquanta, M. Infantino, N. Bizzaro, Detecting Autoantibodies by Multiparametric Assays: Impact on Prevention, Diagnosis, Monitoring, and Personalized Therapy in Autoimmune Diseases, *The Journal of Applied Laboratory Medicine*. 7 (2022) 137–150. <https://doi.org/10.1093/jalm/jfab132>.
30. M.O. Borghi, M. Bombaci, C. Bodio, P.A. Lonati, A. Gobbi, M. Lorenzo, E. Torresani, A. Dubini, I. Bulgarelli, F. Solari, F. Pregnolato, A. Bandera, A. Gori, G. Parati, S. Abrignani, R. Grifantini, P.L. Meroni, Anti-Phospholipid Antibodies and Coronavirus Disease 2019: Vaccination Does Not Trigger Early Autoantibody Production in Healthcare Workers, *Front. Immunol.* 13 (2022) 930074. <https://doi.org/10.3389/fimmu.2022.930074>.
31. A. Banerjee, A. Ray, A. Barpanda, A. Dash, I. Gupta, M.U. Nissa, H. Zhu, A. Shah, S.P. Duttgupta, A. Goel, S. Srivastava, Evaluation of autoantibody signatures in pituitary adenoma patients using human proteome arrays, *Proteomics Clinical Apps.* 16 (2022) 2100111. <https://doi.org/10.1002/prca.202100111>.
32. H.R. Ahn, G.O. Baek, M.G. Yoon, J.A. Son, J.H. Yoon, J.Y. Cheong, H.J. Cho, H.C. Kang, J.W. Eun, S.S. Kim, Hypomethylation-mediated upregulation of the WASF2 promoter region correlates with poor clinical outcomes in hepatocellular carcinoma, *J Exp Clin Cancer Res.* 41 (2022) 158. <https://doi.org/10.1186/s13046-022-02365-7>.
33. A.K.H. Wong, I. Woodhouse, F. Schneider, D.A. Kulpa, G. Silvestri, C.L. Maier, Broad auto-reactive IgM responses are common in critically ill patients, including those with COVID-19, *Cell Reports Medicine*. 2 (2021) 100321. <https://doi.org/10.1016/j.xcrm.2021.100321>.
34. X. Wen, G. Song, C. Hu, J. Pan, Z. Wu, L. Li, C. Liu, X. Tian, F. Zhang, J. Qian, H. Zhu, Y. Li, Identification of Novel Serological Autoantibodies in Takayasu Arteritis Patients Using HuProt Arrays, *Molecular & Cellular Proteomics*. 20 (2021) 100036. <https://doi.org/10.1074/mcp.RA120.002119>.
35. C. Qiu, B. Wang, P. Wang, X. Wang, Y. Ma, L. Dai, J. Shi, K. Wang, G. Sun, H. Ye, J. Zhang, Identification of novel autoantibody signatures and evaluation of a panel of autoantibodies in breast cancer, *Cancer Sci.* 112 (2021) 3388–3400. <https://doi.org/10.1111/cas.15021>.
36. C.P. Moritz, Y. Tholance, O. Stoevesandt, K. Ferraud, J.-P. Camdessanché, J.-C. Antoine, CIDP Antibodies Target Junction Proteins and Identify Patient Subgroups: An Autoantigenomic Approach, *Neurol Neuroimmunol Neuroinflamm.* 8 (2021) e944. <https://doi.org/10.1212/NXI.0000000000000944>.
37. C.P. Moritz, O. Stoevesandt, Y. Tholance, J.-P. Camdessanché, J.-C. Antoine, Proper definition of the set of autoantibody-targeted antigens relies on appropriate reference group selection, *New Biotechnology*. 60 (2021) 168–172. <https://doi.org/10.1016/j.nbt.2020.08.007>.
38. R. McGregor, M.L. Tay, L.H. Carlton, P. Hanson-Manful, J.M. Raynes, W.O. Forsyth, D.T. Brewster, M.J. Middleditch, J. Bennett, W.J. Martin, N. Wilson, P. Atatoa Carr, M.G. Baker, N.J. Moreland, Mapping Autoantibodies in Children With Acute Rheumatic Fever, *Front. Immunol.* 12 (2021) 702877. <https://doi.org/10.3389/fimmu.2021.702877>.
39. M.A. Hutchinson, H.-S. Park, K.J. Zanotti, J. Alvarez-Gonzalez, J. Zhang, L. Zhang, R. Telljohann, M. Wang, E.G. Lakatta, P.J. Gearhart, R.W. Maul, Auto-Antibody Production During Experimental Atherosclerosis in ApoE^{-/-} Mice, *Front. Immunol.* 12 (2021) 695220. <https://doi.org/10.3389/fimmu.2021.695220>.
40. C. Cui, Y. Duan, C. Qiu, P. Wang, G. Sun, H. Ye, L. Dai, Z. Han, C. Song, K. Wang, J. Shi, J. Zhang, Identification of Novel Autoantibodies Based on the Human Proteomic Chips and Evaluation of Their Performance in the Detection of Gastric Cancer, *Front. Oncol.* 11 (2021) 637871. <https://doi.org/10.3389/fonc.2021.637871>.
41. S. Zhang, Y. Liu, J. Chen, H. Shu, S. Shen, Y. Li, X. Lu, X. Cao, L. Dong, J. Shi, Y. Cao, X. Wang, J. Zhou, Y. Liu, L. Chen, J. Fan, G. Ding, Q. Gao, Autoantibody signature in hepatocellular carcinoma using seromics, *J Hematol Oncol.* 13 (2020) 85. <https://doi.org/10.1186/s13045-020-00918-x>.
42. P. Zaenker, D. Prentice, M. Ziman, Tropomyosin autoantibodies associated with checkpoint inhibitor myositis, *Oncol Immunology*. 9 (2020) 1804703. <https://doi.org/10.1080/2162402X.2020.1804703>.
43. A.H. Rowley, S.C. Baker, D. Arrollo, L.J. Gruen, T. Bodnar, N. Innocentini, M. Hackbart, Y.E. Cruz-Pulido, K.M. Wylie, K.-Y.A. Kim, S.T. Shulman, A Protein Epitope Targeted by the Antibody Response to Kawasaki Disease, *The Journal of Infectious Diseases*. 222 (2020) 158–168. <https://doi.org/10.1093/infdis/jiaa066>.
44. J. Pan, L. Yu, Q. Wu, X. Lin, S. Liu, S. Hu, C. Rosa, D. Eichinger, I. Pino, H. Zhu, J. Qian, Y. Huang, Integration of IgA and IgG Autoantigens Improves Performance of Biomarker Panels for Early Diagnosis of Lung Cancer, *Molecular Cellular Proteomics*.

- 19 (2020) 490–500.
<https://doi.org/10.1074/mcp.RA119.001905>.
45. I. Osman, K.M. Giles, Y. Qian, M. Wind-Rotolo, J. Loffredo, T. Hulett, J.S. Weber, H. Zhong, Using autoantibody signatures to predict immunotherapy discontinuation in melanoma patients., *JCO*. 38 (2020) 3069–3069.
https://doi.org/10.1200/JCO.2020.38.15_suppl.3069.
46. E.J. Needham, O. Stoevesandt, E.P. Thelin, H. Zetterberg, E.R. Zanier, F.A. Nimer, N.J. Ashton, J.G. Outtrim, V.F. Newcombe, H.S. Mousa, J. Simren, K. Blennow, Z. Yang Z, P.J. Hutchinson, F. Piehl, A.E. Helmy, M.J. Taussig, K.K. Wang, J.L. Jones, D.K. Menon, A.J. Coles, Complex Autoantibody Responses Occur Following Moderate to Severe Traumatic Brain Injury, *Neurology*, 2020.
<https://doi.org/10.1101/2020.07.24.20161786>.
47. A. Ma, L. Wen, J. Yin, Y. Hu, X. Yue, J. Li, X. Dong, Y. Gupta, R.J. Ludwig, S. Krauss-Etschmann, G. Riemekasten, F. Petersen, X. Yu, Serum Levels of Autoantibodies Against Extracellular Antigens and Neutrophil Granule Proteins Increase in Patients with COPD Compared to Non-COPD Smokers, *COPD*. Volume 15 (2020) 189–200.
<https://doi.org/10.2147/COPD.S235903>.
48. S. Longobardi, C. Lopez-Davis, B. Khatri, C. Georgescu, C. Pritchett-Frazee, C. Lawrence, A. Rasmussen, L. Radfar, R.H. Scofield, A.N. Baer, S.A. Robinson, E. Darrah, R.C. Axtell, G. Pardo, J.D. Wren, K.A. Koelsch, J.M. Guthridge, J.A. James, C.J. Lessard, A.D. Farris. Autoantibodies identify primary Sjögren's syndrome in patients lacking serum IgG specific for Ro/SS-A and La/SS-B. *Annals of the rheumatic diseases*, 82(9) (2023) 1181–1190.
<https://doi.org/10.1136/ard-2022-223105>
49. H.-Z. Ling, S.-Z. Xu, R.-X. Leng, J. Wu, H.-F. Pan, Y.-G. Fan, B. Wang, Y.-R. Xia, Q. Huang, Z.-W. Shuai, D.-Q. Ye, Discovery of new serum biomarker panels for systemic lupus erythematosus diagnosis, *Rheumatology*. 59 (2020) 1416–1425.
<https://doi.org/10.1093/rheumatology/kez634>.
50. Y. Li, C. Li, S. Guo, W. Guo, H. Jiang, H. Li, S. Tao, Longitudinal serum autoantibody repertoire profiling identifies surgery-associated biomarkers in lung adenocarcinoma, *EBioMedicine*. 53 (2020) 102674.
<https://doi.org/10.1016/j.ebiom.2020.102674>.
51. S.S. Kim, S. Shen, S. Miyauchi, P.D. Sanders, I. Franiak-Pietryga, L. Mell, J.S. Gutkind, E.E.W. Cohen, J.A. Califano, A.B. Sharabi, B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade, *Clinical Cancer Research*. 26 (2020) 3345–3359.
<https://doi.org/10.1158/1078-0432.CCR-19-3211>.
52. C.N. Gruber, R.S. Patel, R. Trachtman, L. Lepow, F. Amanat, F. Krammer, K.M. Wilson, K. Onel, D. Geanon, K. Tuballes, M. Patel, K. Mouskas, T. O'Donnell, E. Merritt, N.W. Simons, V. Barcessat, D.M. Del Valle, S. Udondem, G. Kang, S. Gangadharan, G. Ofori-Amanfo, U. Laserson, A. Rahman, S. Kim-Schulze, A.W. Charney, S. Gnjatic, B.D. Gelb, M. Merad, D. Bogunovic, Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C), *Cell*. 183 (2020) 982-995.e14.
<https://doi.org/10.1016/j.cell.2020.09.034>.
53. I.S. Dhande, Y. Zhu, S.C. Kneedler, A.S. Joshi, M.J. Hicks, S.E. Wenderfer, M.C. Braun, P.A. Doris, Stim1 Polymorphism Disrupts Immune Signaling and Creates Renal Injury in Hypertension, *JAHA*. 9 (2020) e014142.
<https://doi.org/10.1161/JAHA.119.014142>.
54. I.S. Dhande, S.C. Kneedler, Y. Zhu, A.S. Joshi, M.J. Hicks, S.E. Wenderfer, M.C. Braun, P.A. Doris, Natural genetic variation in Stim1 creates stroke in the spontaneously hypertensive rat, *Genes Immun*. 21 (2020) 182–192.
<https://doi.org/10.1038/s41435-020-0097-5>.
55. S. Ye, L. Ma, R. Zhang, F. Liu, P. Jiang, J. Xu, H. Cao, X. Du, F. Lin, L. Cheng, X. Zhou, Z. Shi, Y. Liu, Y. Huang, Z. Wang, C. Li, Plasma proteomic and autoantibody profiles reveal the proteomic characteristics involved in longevity families in Bama, China, *Clin Proteom*. 16 (2019) 22.
<https://doi.org/10.1186/s12014-019-9242-4>.
56. K.J. Lastwika, J. Kargl, Y. Zhang, X. Zhu, E. Lo, D. Shelley, J.J. Ladd, W. Wu, P. Kinahan, S.N.J. Pipavath, T.W. Randolph, M. Shipley, P.D. Lampe, A.M. Houghton, Tumor-derived Autoantibodies Identify Malignant Pulmonary Nodules, *Am J Respir Crit Care Med*. 199 (2019) 1257–1266.
<https://doi.org/10.1164/rccm.201804-0628OC>.
57. M.F. Gowen, K.M. Giles, D. Simpson, J. Tchack, H. Zhou, U. Moran, Z. Dawood, A.C. Pavlick, S. Hu, M.A. Wilson, H. Zhong, M. Krogsgaard, T. Kirchhoff, I. Osman, Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors, *J Transl Med*. 16 (2018) 82.
<https://doi.org/10.1186/s12967-018-1452-4>.
58. J.M. Chung, Y. Jung, Y.P. Kim, J. Song, S. Kim, J.Y. Kim, M. Kwon, J.H. Yoon, M.-D. Kim, J. Lee, D.-Y. Chung, S.Y. Lee, J. Kang, H.C. Kang, Identification

- of the Thioredoxin-Like 2 Autoantibody as a Specific Biomarker for Triple-Negative Breast Cancer, *J Breast Cancer*. 21 (2018) 87.
<https://doi.org/10.4048/jbc.2018.21.1.87>.
59. H.D. Bremer, N. Landegren, R. Sjöberg, Å. Hallgren, S. Renneker, E. Lattwein, D. Leonard, M.-L. Eloranta, L. Rönnblom, G. Nordmark, P. Nilsson, G. Andersson, I. Lilliehöök, K. Lindblad-Toh, O. Kämpe, H. Hansson-Hamlin, ILF2 and ILF3 are autoantigens in canine systemic autoimmune disease, *Sci Rep*. 8 (2018) 4852.
<https://doi.org/10.1038/s41598-018-23034-w>.
 60. J. Wang, J. You, L. Wang, H. Wang, T. Tian, W. Wang, L. Jia, C. Jiang, PTMA, a new identified autoantigen for oral submucous fibrosis, regulates oral submucous fibroblast proliferation and extracellular matrix, *Oncotarget*. 8 (2017) 74806–74819.
<https://doi.org/10.18632/oncotarget.20419>.
 61. S. Gupta, S. Mukherjee, P. Syed, N.G. Pandala, S. Choudhary, V.A. Singh, N. Singh, H. Zhu, S. Epari, S.B. Noronha, A. Moiyadi, S. Srivastava, Evaluation of autoantibody signatures in meningioma patients using human proteome arrays, *Oncotarget*. 8 (2017) 58443–58456.
<https://doi.org/10.18632/oncotarget.16997>.
 62. S. Gupta, K.P. Manubhai, S. Mukherjee, S. Srivastava, Serum Profiling for Identification of Autoantibody Signatures in Diseases Using Protein Microarrays, in: D.W. Greening, R.J. Simpson (Eds.), *Serum/Plasma Proteomics*, Springer New York, New York, NY, 2017: pp. 303–315.
https://doi.org/10.1007/978-1-4939-7057-5_21.
 63. B.K. Chung, B.T. Guevel, G.M. Reynolds, D.B.R.K. Gupta Udatha, E.K.K. Henriksen, Z. Stamataki, G.M. Hirschfield, T.H. Karlsen, E. Liaskou, Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis, *Journal of Autoimmunity*. 77 (2017) 45–54.
<https://doi.org/10.1016/j.jaut.2016.10.003>.
 64. L. Yang, J. Wang, J. Li, H. Zhang, S. Guo, M. Yan, Z. Zhu, B. Lan, Y. Ding, M. Xu, W. Li, X. Gu, C. Qi, H. Zhu, Z. Shao, B. Liu, S.-C. Tao, Identification of Serum Biomarkers for Gastric Cancer Diagnosis Using a Human Proteome Microarray, *Molecular Cellular Proteomics*. 15 (2016) 614–623.
<https://doi.org/10.1074/mcp.M115.051250>.
 65. M. Ogishi, H. Yotsuyanagi, K. Moriya, K. Koike, Delineation of autoantibody repertoire through differential proteogenomics in hepatitis C virus-induced cryoglobulinemia, *Sci Rep*. 6 (2016) 29532.
<https://doi.org/10.1038/srep29532>.
 66. D.F. Fiorentino, M. Presby, A.N. Baer, M. Petri, K.E. Rieger, M. Soloski, A. Rosen, A.L. Mammen, L. Christopher-Stine, L. Casciola-Rosen, PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome, *Ann Rheum Dis*. 75 (2016) 1145–1151.
<https://doi.org/10.1136/annrheumdis-2015-207509>.
 67. P. Syed, S. Gupta, S. Choudhary, N.G. Pandala, A. Atak, A. Richharia, M. Kp, H. Zhu, S. Epari, S.B. Noronha, A. Moiyadi, S. Srivastava, Autoantibody Profiling of Glioma Serum Samples to Identify Biomarkers Using Human Proteome Arrays, *Sci Rep*. 5 (2015) 13895.
<https://doi.org/10.1038/srep13895>.
 68. C. Hu, W. Huang, H. Chen, G. Song, P. Li, Q. Shan, X. Zhang, F. Zhang, H. Zhu, L. Wu, Y. Li, Autoantibody Profiling on Human Proteome Microarray for Biomarker Discovery in Cerebrospinal Fluid and Sera of Neuropsychiatric Lupus, *PLoS ONE*. 10 (2015) e0126643.
<https://doi.org/10.1371/journal.pone.0126643>.
 69. C.-J. Hu, G. Song, W. Huang, G.-Z. Liu, C.-W. Deng, H.-P. Zeng, L. Wang, F.-C. Zhang, X. Zhang, J.S. Jeong, S. Blackshaw, L.-Z. Jiang, H. Zhu, L. Wu, Y.-Z. Li, Identification of New Autoantigens for Primary Biliary Cirrhosis Using Human Proteome Microarrays, *Molecular Cellular Proteomics*. 11 (2012) 669–680.
<https://doi.org/10.1074/mcp.M111.015529>.

8.2 Antibody Specificity and Crossreactivity

1. T. Hotta, Y. Nariyai, N. Kajitani, K. Kadota, R. Maruyama, Y. Tajima, T. Isobe, H. Kamino, T. Urano, Generation of the novel anti-FXYD5 monoclonal antibody and its application to the diagnosis of pancreatic and lung cancer, *Biochimie*. (2023) S0300908423000020.
<https://doi.org/10.1016/j.biochi.2023.01.002>.
2. E. Gomez-Bañuelos, Y. Yu, J. Li, K.S. Cashman, M. Paz, M.I. Trejo-Zambrano, R. Bugrovsky, Y. Wang, A.S. Chida, C.A. Sherman-Baust, D.P. Ferris, D.W. Goldman, E. Darrah, M. Petri, I. Sanz, F. Andrade, Affinity maturation generates pathogenic antibodies with dual reactivity to DNase1L3 and dsDNA in systemic lupus erythematosus, *Nat Commun*. 14 (2023) 1388.
<https://doi.org/10.1038/s41467-023-37083-x>.
3. T.V. Lanz, R.C. Brewer, P.P. Ho, J.-S. Moon, K.M. Jude, D. Fernandez, R.A. Fernandes, A.M. Gomez, G.-S. Nadj, C.M. Bartley, R.D. Schubert, I.A. Hawes, S.E. Vazquez, M. Iyer, J.B. Zuchero, B. Teegen, J.E. Dunn, C.B. Lock, L.B. Kipp, V.C. Cotham, B.M.

- Ueberheide, B.T. Aftab, M.S. Anderson, J.L. DeRisi, M.R. Wilson, R.J.M. Bashford-Rogers, M. Platten, K.C. Garcia, L. Steinman, W.H. Robinson, Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM, *Nature*. (2022) 1–12. <https://doi.org/10.1038/s41586-022-04432-7>.
4. C. Castrillon, L. Simoni, T. Van Den Broek, C. Van Der Poel, E.H. Akama-Garren, M. Ma, M.C. Carroll, Complex subsets but redundant clonality after B cells egress from spontaneous germinal centers, *Immunology*, 2022. <https://doi.org/10.1101/2022.06.21.496939>.
 5. T.K. MacLachlan, S. Price, J. Cavagnaro, L. Andrews, D. Blanset, M.E. Cosenza, M. Dempster, E. Galbreath, A.M. Giusti, K.M. Heinz-Taheny, R. Fleurance, E. Sutter, M.W. Leach, Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules – A survey of industry 2008–2019, *Regulatory Toxicology and Pharmacology*. 121 (2021) 104872. <https://doi.org/10.1016/j.yrtph.2021.104872>.
 6. Y.C. Kim, J. Lee, J.N. An, J.H. Kim, Y.-W. Choi, L. Li, S.H. Kwon, M.-Y. Lee, B. Lee, J.-G. Jeong, S.-S. Yu, C.S. Lim, Y.S. Kim, S. Kim, S.H. Yang, J.P. Lee, Renoprotective effects of a novel cMet agonistic antibody on kidney fibrosis, *Sci Rep*. 9 (2019) 13495. <https://doi.org/10.1038/s41598-019-49756-z>.
 7. A. Venkataraman, K. Yang, J. Irizarry, M. Mackiewicz, P. Mita, Z. Kuang, L. Xue, D. Ghosh, S. Liu, P. Ramos, S. Hu, D. Bayron Kain, S. Keegan, R. Saul, S. Colantonio, H. Zhang, F.P. Behn, G. Song, E. Albino, L. Asencio, L. Ramos, L. Lugo, G. Morell, J. Rivera, K. Ruiz, R. Almodovar, L. Nazario, K. Murphy, I. Vargas, Z.A. Rivera-Pacheco, C. Rosa, M. Vargas, J. McDade, B.S. Clark, S. Yoo, S.G. Khambadkone, J. De Melo, M. Stevanovic, L. Jiang, Y. Li, W.Y. Yap, B. Jones, A. Tandon, E. Campbell, G.T. Montelione, S. Anderson, R.M. Myers, J.D. Boeke, D. Fenyö, G. Whiteley, J.S. Bader, I. Pino, D.J. Eichinger, H. Zhu, S. Blackshaw, A toolbox of immunoprecipitation-grade monoclonal antibodies to human transcription factors, *Nat Methods*. 15 (2018) 330–338. <https://doi.org/10.1038/nmeth.4632>.
 8. P. Ramos-López, J. Irizarry, I. Pino, S. Blackshaw, Antibody Specificity Profiling Using Protein Microarrays, in: J. Rockberg, J. Nilvebrant (Eds.), *Epitope Mapping Protocols*, Springer New York, New York, NY, 2018: pp. 223–229. https://doi.org/10.1007/978-1-4939-7841-0_14.
 9. N. Washburn, R. Meccariello, S. Hu, M. Hains, N. Bhatnagar, H. Sarvaiya, B. Kapoor, J. Schaeck, I. Pino, A. Manning, J.C. Lansing, C.J. Bosques, High-resolution physicochemical characterization of different intravenous immunoglobulin products, *PLoS ONE*. 12 (2017) e0181251. <https://doi.org/10.1371/journal.pone.0181251>.
 10. E. Sterner, M.L. Peach, M.C. Nicklaus, J.C. Gilder-sleeve, Therapeutic Antibodies to Ganglioside GD2 Evolved from Highly Selective Germline Antibodies, *Cell Reports*. 20 (2017) 1681–1691. <https://doi.org/10.1016/j.celrep.2017.07.050>.
 11. J.S. Jeong, L. Jiang, E. Albino, J. Marrero, H.S. Rho, J. Hu, S. Hu, C. Vera, D. Bayron-Poueymiroy, Z.A. Rivera-Pacheco, L. Ramos, C. Torres-Castro, J. Qian, J. Bonaventura, J.D. Boeke, W.Y. Yap, I. Pino, D.J. Eichinger, H. Zhu, S. Blackshaw, Rapid Identification of Monospecific Monoclonal Antibodies Using a Human Proteome Microarray, *Molecular Cellular Proteomics*. 11 (2012) O111.016253. <https://doi.org/10.1074/mcp.O111.016253>.

8.3 Protein Interactomics

1. S. Yamada, T. Ko, M. Ito, T. Sassa, S. Nomura, H. Okuma, M. Sato, T. Imasaki, S. Kikkawa, B. Zhang, T. Yamada, Y. Seki, K. Fujita, M. Katoh, M. Kubota, S. Hatsuse, M. Katagiri, H. Hayashi, M. Hamano, N. Takeda, H. Morita, S. Takada, M. Toyoda, M. Uchiyama, M. Ikeuchi, K. Toyooka, A. Umezawa, Y. Yamanishi, R. Nitta, H. Aburatani, I. Komuro, TEAD1 trapping by the Q353R–Lamin A/C causes dilated cardiomyopathy, *Sci. Adv*. 9 (2023) eade7047. <https://doi.org/10.1126/sciadv.ade7047>.
2. M. Potez, S. Snedal, C. She, J. Kim, K. Thorner, T.H. Tran, M.C. Ramello, D. Abate-Daga, J.K.C. Liu, Use of phage display biopanning as a tool to design CAR-T cells against glioma stem cells, *Front. Oncol*. 13 (2023) 1124272. <https://doi.org/10.3389/fonc.2023.1124272>.
3. H. Li, F. Liu, H. Kuang, H. Teng, S. Chen, S. Zeng, Q. Zhou, Z. Li, D. Liang, Z. Li, L. Wu, WDR73 Depletion Destabilizes PIP4K2C Activity and Impairs Focal Adhesion Formation in Galloway–Mowat Syndrome, *Biology*. 11 (2022) 1397. <https://doi.org/10.3390/biology11101397>.
4. H.M. Kang, D.H. Kim, M. Kim, Y. Min, B. Jeong, K.H. Noh, D.Y. Lee, H.-S. Cho, N.-S. Kim, C.-R. Jung, J.H. Lim, FBXL17/spastin axis as a novel therapeutic target of hereditary spastic paraplegia, *Cell Biosci*. 12 (2022) 110. <https://doi.org/10.1186/s13578-022-00851-1>.
5. L. Zhou, Y. Ge, Y. Fu, B. Wu, Y. Zhang, L. Li, C.-P. Cui, S. Wang, L. Zhang, Global Screening of

- LUBAC and OTULIN Interacting Proteins by Human Proteome Microarray, *Front. Cell Dev. Biol.* 9 (2021) 686395.
<https://doi.org/10.3389/fcell.2021.686395>.
6. L. Zhang, J. Zhou, M. Xu, G. Yuan, Exploration of the Hsa-miR-1587-Protein Interaction and the Inhibition to CASK, *IJMS.* 22 (2021) 10716.
<https://doi.org/10.3390/ijms221910716>.
7. X. Wan, L. Zhu, L. Zhao, L. Peng, J. Xiong, W. Yang, J. Yuan, F. Liang, K. Zhang, K. Chen, hPER3 promotes adipogenesis via hHSP90AA1-mediated inhibition of Notch1 pathway, *Cell Death Dis.* 12 (2021) 301.
<https://doi.org/10.1038/s41419-021-03584-0>.
8. G. Song, E.M. Lee, J. Pan, M. Xu, H.-S. Rho, Y. Cheng, N. Whitt, S. Yang, J. Kouznetsova, C. Klumpp-Thomas, S.G. Michael, C. Moore, K.-J. Yoon, K.M. Christian, A. Simeonov, W. Huang, M. Xia, R. Huang, M. Lal-Nag, H. Tang, W. Zheng, J. Qian, H. Song, G. Ming, H. Zhu, An Integrated Systems Biology Approach Identifies the Proteasome as A Critical Host Machinery for ZIKV and DENV Replication, *Genomics, Proteomics Bioinformatics.* 19 (2021) 108–122.
<https://doi.org/10.1016/j.gpb.2020.06.016>.
9. T. Reiter, S. Pajenda, D. O'Connell, C. Lynch, S. Kapps, H. Agis, A. Schmidt, L. Wagner, N. Leung, W. Winnicki, Renal Expression of Light Chain Binding Proteins, *Front. Med.* 7 (2021) 609582.
<https://doi.org/10.3389/fmed.2020.609582>.
10. A.M. Haapalainen, R. Daddali, M. Hallman, M. R  met, Human CPPED1 belongs to calcineurin-like metallophosphoesterase superfamily and dephosphorylates PI3K-AKT pathway component PAK4, *J Cell Mol Med.* 25 (2021) 6304–6317.
<https://doi.org/10.1111/jcmm.16607>.
11. S.-Y. Kim, H.J. Kim, H.J. Kim, C.-H. Kim, Non-Thermal Plasma Induces Antileukemic Effect Through mTOR Ubiquitination, *Cells.* 9 (2020) 595.
<https://doi.org/10.3390/cells9030595>.
12. G. Song, L. Chen, B. Zhang, Q. Song, Y. Yu, C. Moore, T.-L. Wang, I.-M. Shih, H. Zhang, D.W. Chan, Z. Zhang, H. Zhu, Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors, *Molecular Cellular Proteomics.* 18 (2019) 448–460.
<https://doi.org/10.1074/mcp.RA118.000851>.
13. T. Cao, L. Lyu, H. Jia, J. Wang, F. Du, L. Pan, Z. Li, A. Xing, J. Xiao, Y. Ma, Z. Zhang, A Two-Way Proteome Microarray Strategy to Identify Novel Mycobacterium tuberculosis-Human Interactors, *Front. Cell. Infect. Microbiol.* 9 (2019) 65.
<https://doi.org/10.3389/fcimb.2019.00065>.
14. F.-L. Wu, Y. Liu, H.-N. Zhang, H.-W. Jiang, L. Cheng, S.-J. Guo, J.-Y. Deng, L.-J. Bi, X.-E. Zhang, H.-F. Gao, S.-C. Tao, Global Profiling of PknG Interactions Using a Human Proteome Microarray Reveals Novel Connections with CypA, *Proteomics.* 18 (2018) 1800265.
<https://doi.org/10.1002/pmic.201800265>.
15. Y. Wang, X. Weng, L. Wang, M. Hao, Y. Li, L. Hou, Y. Liang, T. Wu, M. Yao, G. Lin, Y. Jiang, G. Fu, Z. Hou, X. Meng, J. Lu, J. Wang, HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk, *Journal of Clinical Investigation.* 128 (2018) 5235–5250.
<https://doi.org/10.1172/JCI99974>.
16. M. Liu, Y. Ru, Y. Gu, J. Tang, T. Zhang, J. Wu, F. Yu, Y. Yuan, C. Xu, J. Wang, H. Shi, Disruption of Ssp411 causes impaired sperm head formation and male sterility in mice, *Biochimica et Biophysica Acta (BBA) – General Subjects.* 1862 (2018) 660–668.
<https://doi.org/10.1016/j.bbagen.2017.12.005>.
17. G. Guo, S. Ye, S. Xie, L. Ye, C. Lin, M. Yang, X. Shi, F. Wang, B. Li, M. Li, C. Chen, L. Zhang, H. Zhang, X. Xue, The cytomegalovirus protein US31 induces inflammation through mono-macrophages in systemic lupus erythematosus by promoting NF-B2 activation, *Cell Death Dis.* 9 (2018) 104.
<https://doi.org/10.1038/s41419-017-0122-4>.
18. Y. Feng, C.-S. Chen, J. Ho, D. Pearce, S. Hu, B. Wang, P. Desai, K.S. Kim, H. Zhu, High-Throughput Chip Assay for Investigating Escherichia coli Interaction with the Blood-Brain Barrier Using Microbial and Human Proteome Microarrays (Dual-Microarray Technology), *Anal. Chem.* 90 (2018) 10958–10966.
<https://doi.org/10.1021/acs.analchem.8b02513>.
19. S.-W. Choi, H.-H. Park, S. Kim, J.M. Chung, H.-J. Noh, S.K. Kim, H.K. Song, C.-W. Lee, M.J. Morgan, H.C. Kang, Y.-S. Kim, PEL1 Selectively Targets Kinase-Active RIP3 for Ubiquitylation-Dependent Proteasomal Degradation, *Molecular Cell.* 70 (2018) 920-935.e7.
<https://doi.org/10.1016/j.molcel.2018.05.016>.
20. Y. Bao, F. Yang, B. Liu, T. Zhao, Z. Xu, Y. Xiong, S. Sun, L. Qu, L. Wang, Angiopoietin-like protein 3 blocks nuclear import of FAK and contributes to sorafenib response, *Br J Cancer.* 119 (2018) 450–461.
<https://doi.org/10.1038/s41416-018-0189-4>.
21. N. Washburn, R. Meccariello, S. Hu, M. Hains, N. Bhatnagar, H. Sarvaiya, B. Kapoor, J. Schaeck,

- I. Pino, A. Manning, J.C. Lansing, C.J. Bosques, High-resolution physicochemical characterization of different intravenous immunoglobulin products, *PLoS ONE*. 12 (2017) e0181251. <https://doi.org/10.1371/journal.pone.0181251>.
22. E. Cox, W. Hwang, I. Uzoma, J. Hu, C.M. Guzzo, J. Jeong, M.J. Matunis, J. Qian, H. Zhu, S. Blackshaw, Global Analysis of SUMO-Binding Proteins Identifies SUMOylation as a Key Regulator of the INO80 Chromatin Remodeling Complex, *Molecular Cellular Proteomics*. 16 (2017) 812–823. <https://doi.org/10.1074/mcp.M116.063719>.
23. Y. Wang, R. An, G.K. Umanah, H. Park, K. Nambiar, S.M. Eacker, B. Kim, L. Bao, M.M. Harraz, C. Chang, R. Chen, J.E. Wang, T.-I. Kam, J.S. Jeong, Z. Xie, S. Neifert, J. Qian, S.A. Andrabi, S. Blackshaw, H. Zhu, H. Song, G. Ming, V.L. Dawson, T.M. Dawson, A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1, *Science*. 354 (2016) aad6872. <https://doi.org/10.1126/science.aad6872>.
24. H. Li, S. Edie, D. Klinedinst, J.S. Jeong, S. Blackshaw, C.L. Maslen, R.H. Reeves, Penetrance of Congenital Heart Disease in a Mouse Model of Down Syndrome Depends on a Trisomic Potentiator of a Disomic Modifier, *Genetics*. 203 (2016) 763–770. <https://doi.org/10.1534/genetics.116.188045>.
25. J.S. Ainscough, G.F. Gerberick, I. Kimber, R.J. Dearman, Interleukin-1 Processing Is Dependent on a Calcium-mediated Interaction with Calmodulin, *Journal of Biological Chemistry*. 290 (2015) 31151–31161. <https://doi.org/10.1074/jbc.M115.680694>.
26. T.M. Ma, B.D. Paul, C. Fu, S. Hu, H. Zhu, S. Blackshaw, H. Wolosker, S.H. Snyder, Serine Racemase Regulated by Binding to Stargazin and PSD-95, *Journal of Biological Chemistry*. 289 (2014) 29631–29641. <https://doi.org/10.1074/jbc.M114.571604>.
27. J.-G. Jung, A. Stoeck, B. Guan, R.-C. Wu, H. Zhu, S. Blackshaw, I.-M. Shih, T.-L. Wang, Notch3 Interactome Analysis Identified WWP2 as a Negative Regulator of Notch3 Signaling in Ovarian Cancer, *PLoS Genet*. 10 (2014) e1004751. <https://doi.org/10.1371/journal.pgen.1004751>.
28. Q. Fan, L.-Z. Huang, X.-J. Zhu, K.-K. Zhang, H.-F. Ye, Y. Luo, X.-H. Sun, Y. Lu, Identification of proteins that interact with alpha A-crystallin using a human proteome microarray, *Molecular Vision*. (2014).
29. R.-P. Deng, X. He, S.-J. Guo, W.-F. Liu, Y. Tao, S.-C. Tao, Global identification of O -GlcNAc transferase (OGT) interactors by a human proteome microarray and the construction of an OGT interactome, *Proteomics*. 14 (2014) 1020–1030. <https://doi.org/10.1002/pmic.201300144>.
30. Y. Chen, L.-N. Yang, L. Cheng, S. Tu, S.-J. Guo, H.-Y. Le, Q. Xiong, R. Mo, C.-Y. Li, J.-S. Jeong, L. Jiang, S. Blackshaw, L.-J. Bi, H. Zhu, S.-C. Tao, F. Ge, Bcl2-associated Athanogene 3 Interactome Analysis Reveals a New Role in Modulating Proteasome Activity, *Molecular & Cellular Proteomics*. 12 (2013) 2804–2819. <https://doi.org/10.1074/mcp.M112.025882>.
31. Y. Huang, J.S. Jeong, J. Okamura, M. Sook-Kim, H. Zhu, R. Guerrero-Preston, E.A. Ratovitski, Global tumor protein p53/p63 interactome: Making a case for cisplatin chemoresistance, *Cell Cycle*. 11 (2012) 2367–2379. <https://doi.org/10.4161/cc.20863>.

8.4 Enzymatic Assays

1. S.-H. Kim, Y.-S. Cho, Y. Kim, J. Park, S.-M. Yoo, J. Gwak, Y. Kim, Y. Gwon, T. Kam, Y.-K. Jung, Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and rescue via the HYAL-CD44 axis in Alzheimer disease, *Autophagy*. (2023) 1–20. <https://doi.org/10.1080/15548627.2023.2181614>.
2. T.V. Lanz, R.C. Brewer, P.P. Ho, J.-S. Moon, K.M. Jude, D. Fernandez, R.A. Fernandes, A.M. Gomez, G.-S. Nadj, C.M. Bartley, R.D. Schubert, I.A. Hawes, S.E. Vazquez, M. Iyer, J.B. Zuchero, B. Teegen, J.E. Dunn, C.B. Lock, L.B. Kipp, V.C. Cotham, B.M. Ueberheide, B.T. Aftab, M.S. Anderson, J.L. DeRisi, M.R. Wilson, R.J.M. Bashford-Rogers, M. Platten, K.C. Garcia, L. Steinman, W.H. Robinson, Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM, *Nature*. 603 (2022) 321–327. <https://doi.org/10.1038/s41586-022-04432-7>.
3. H. Jiang, C.Y. Chiang, Z. Chen, S. Nathan, G. D'Agostino, J.A. Paulo, G. Song, H. Zhu, S.B. Gabelli, P.A. Cole, Enzymatic analysis of WWP2 E3 ubiquitin ligase using protein microarrays identifies autophagy-related substrates, *Journal of Biological Chemistry*. 298 (2022) 101854. <https://doi.org/10.1016/j.jbc.2022.101854>.
4. M.J. Cabello-Lobato, M. Jenner, M. Cisneros-Aguirre, K. Brüninghoff, Z. Sandy, I.C. da Costa, T.A. Jowitt, C.M. Loch, S.P. Jackson, Q. Wu, H.D. Mootz, J.M. Stark, M.J. Cliff, C.K. Schmidt, Microarray screening reveals two non-conventional SUMO-binding modules linked to DNA repair by non-homologous

- end-joining, *Nucleic Acids Research*. 50 (2022) 4732–4754.
<https://doi.org/10.1093/nar/gkac237>.
5. Y. Yan, A. Narayan, S. Cho, Z. Cheng, J.O. Liu, H. Zhu, G. Wang, B. Wharram, A. Lisok, M. Brummet, H. Saeki, T. Huang, K. Gabrielson, E. Gabrielson, L. Cope, Y.M. Kanaan, A. Afsari, T. Naab, H.G. Yfantis, S. Ambs, M.G. Pomper, S. Sukumar, V.F. Merino, CRYB2 enhances tumorigenesis through upregulation of nucleolin in triple negative breast cancer, *Oncogene*. 40 (2021) 5752–5763.
<https://doi.org/10.1038/s41388-021-01975-3>.
6. L.J. Crawford, D.C. Campbell, J.J. Morgan, M.A. Lawson, J.M. Down, D. Chauhan, R.M. McAvera, T.C. Morris, C. Hamilton, A. Krishnan, K. Rajalingam, A.D. Chantry, A.E. Irvine, The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma, *Oncogene*. 39 (2020) 5001–5014.
<https://doi.org/10.1038/s41388-020-1345-x>.
7. J. Chen, C. Sagum, M.T. Bedford, Protein domain microarrays as a platform to decipher signaling pathways and the histone code, *Methods*. 184 (2020) 4–12.
<https://doi.org/10.1016/j.ymeth.2019.08.007>.
8. I. Uzoma, J. Hu, E. Cox, S. Xia, J. Zhou, H.-S. Rho, C. Guzzo, C. Paul, O. Ajala, C.R. Goodwin, J. Jeong, C. Moore, H. Zhang, P. Meluh, S. Blackshaw, M. Matunis, J. Qian, H. Zhu, Global Identification of Small Ubiquitin-related Modifier (SUMO) Substrates Reveals Crosstalk between SUMOylation and Phosphorylation Promotes Cell Migration, *Molecular Cellular Proteomics*. 17 (2018) 871–888.
<https://doi.org/10.1074/mcp.RA117.000014>.
9. G. Song, H.-S. Rho, J. Pan, P. Ramos, K.-J. Yoon, F.A. Medina, E.M. Lee, D. Eichinger, G. Ming, J.L. Muñoz-Jordan, H. Tang, I. Pino, H. Song, J. Qian, H. Zhu, Multiplexed Biomarker Panels Discriminate Zika and Dengue Virus Infection in Humans, *Molecular & Cellular Proteomics*. 17 (2018) 349–356.
<https://doi.org/10.1074/mcp.RA117.000310>.
10. Z. Xu, X. Li, S. Zhou, W. Xie, J. Wang, L. Cheng, S. Wang, S. Guo, Z. Xu, X. Cao, M. Zhang, B. Yu, H. Narimatsu, S. Tao, Y. Zhang, Systematic identification of the protein substrates of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-T1/T2/T3 using a human proteome microarray, *Proteomics*. 17 (2017) 1600485.
<https://doi.org/10.1002/pmic.201600485>.
11. J. Hu, J. Neiswinger, J. Zhang, H. Zhu, J. Qian, Systematic Prediction of Scaffold Proteins Reveals New Design Principles in Scaffold-Mediated Signal Transduction, *PLoS Comput Biol*. 11 (2015) e1004508.
<https://doi.org/10.1371/journal.pcbi.1004508>.
12. E. Cox, I. Uzoma, C. Guzzo, J.S. Jeong, M. Matunis, S. Blackshaw, H. Zhu, Identification of SUMO E3 Ligase-Specific Substrates Using the HuProt Human Proteome Microarray, in: A. Posch (Ed.), *Proteomic Profiling*, Springer New York, New York, NY, 2015: pp. 455–463.
https://doi.org/10.1007/978-1-4939-2550-6_32.
13. Y.-I. Lee, D. Giovinazzo, H.C. Kang, Y. Lee, J.S. Jeong, P.-T. Doulias, Z. Xie, J. Hu, M. Ghasemi, H. Ischiropoulos, J. Qian, H. Zhu, S. Blackshaw, V.L. Dawson, T.M. Dawson, Protein Microarray Characterization of the S-Nitrosoproteome, *Molecular & Cellular Proteomics*. 13 (2014) 63–72.
<https://doi.org/10.1074/mcp.M113.032235>.
14. M.K. Tarrant, H.-S. Rho, Z. Xie, Y.L. Jiang, C. Gross, J.C. Culhane, G. Yan, J. Qian, Y. Ichikawa, T. Matsuo, N. Zachara, F.A. Etzkorn, G.W. Hart, J.S. Jeong, S. Blackshaw, H. Zhu, P.A. Cole, Regulation of CK2 by phosphorylation and O-GlcNAcylation revealed by semisynthesis, *Nat Chem Biol*. 8 (2012) 262–269.
<https://doi.org/10.1038/nchembio.771>.

8.5 Nucleic Acid Binding

1. D. Sun, Y. Wang, N. Sun, Z. Jiang, Z. Li, L. Wang, F. Yang, W. Li, LncRNA DANCER counteracts premature ovarian insufficiency by regulating the senescence process of granulosa cells through stabilizing the interaction between p53 and hNRNPC, *J Ovarian Res*. 16 (2023) 41.
<https://doi.org/10.1186/s13048-023-01115-3>.
2. Q.W. Chen, Q.Q. Cai, Y. Yang, S. Dong, Y.Y. Liu, Z.Y. Chen, C.L. Kang, B. Qi, Y.W. Dong, W. Wu, L.P. Zhuang, Y.H. Shen, Z.Q. Meng, X.Z. Wu, LncRNA BC promotes lung adenocarcinoma progression by modulating IMPAD1 alternative splicing, *Clinical & Translational Med*. 13 (2023).
<https://doi.org/10.1002/ctm2.1129>.
3. D. Van Simaey, A. De La Fuente, S. Zilio, A. Zoso, V. Kuznetsova, O. Alcazar, P. Buchwald, A. Grilli, J. Caroli, S. Biciato, P. Serafini, RNA aptamers specific for transmembrane p24 trafficking protein 6 and Clusterin for the targeted delivery of imaging reagents and RNA therapeutics to human cells, *Nat Commun*. 13 (2022) 1815.
<https://doi.org/10.1038/s41467-022-29377-3>.
4. M.J. Cabello-Lobato, M. Jenner, M. Cisneros-Aguirre, K. Brünninghoff, Z. Sandy, I.C. da Costa, T.A. Jowitt,

- C.M. Loch, S.P. Jackson, Q. Wu, H.D. Mootz, J.M. Stark, M.J. Cliff, C.K. Schmidt, Microarray screening reveals two non-conventional SUMO-binding modules linked to DNA repair by non-homologous end-joining, *Nucleic Acids Research*. 50 (2022) 4732–4754.
<https://doi.org/10.1093/nar/gkac237>.
5. Q. Wang, S. Yi, Z. Du, X. Huang, J. Xu, Q. Cao, G. Su, A. Kijlstra, P. Yang, The Rs12569232 SNP Association with Vogt-Koyanagi-Harada Disease and Behcet's Disease is Probably Mediated by Regulation of Linc00467 Expression, *Ocular Immunology and Inflammation*. 29 (2021) 1464–1470.
<https://doi.org/10.1080/09273948.2020.1745244>.
6. B. Yu, L. Qu, T. Wu, B. Yan, X. Kan, X. Zhao, L. Yang, Y. Li, M. Liu, L. Tian, Y. Sun, Q. Li, A Novel LncRNA, AC091729.7 Promotes Sinonasal Squamous Cell Carcinomas Proliferation and Invasion Through Binding SRSF2, *Front. Oncol.* 9 (2020) 1575.
<https://doi.org/10.3389/fonc.2019.01575>.
7. E. Panatta, A.M. Lena, M. Mancini, A. Smirnov, A. Marini, R. Delli Ponti, T. Botta-Orfila, G.G. Tartaglia, A. Mauriello, X. Zhang, G.A. Calin, G. Melino, E. Candi, Long non-coding RNA uc.291 controls epithelial differentiation by interfering with the ACTL6A/BAF complex, *EMBO Reports*. 21 (2020) e46734.
<https://doi.org/10.15252/embr.201846734>.
8. L. Liu, T. Li, G. Song, Q. He, Y. Yin, J.Y. Lu, X. Bi, K. Wang, S. Luo, Y.-S. Chen, Y. Yang, B.-F. Sun, Y.-G. Yang, J. Wu, H. Zhu, X. Shen, Insight into novel RNA-binding activities via large-scale analysis of lncRNA-bound proteome and IDH1-bound transcriptome, *Nucleic Acids Research*. 47 (2019) 2244–2262.
<https://doi.org/10.1093/nar/gkz032>.
9. C.L. Kang, B. Qi, Q.Q. Cai, L.S. Fu, Y. Yang, C. Tang, P. Zhu, Q.W. Chen, J. Pan, M.H. Chen, X.Z. Wu, LncRNA AY promotes hepatocellular carcinoma metastasis by stimulating ITGAV transcription, *Theranostics*. 9 (2019) 4421–4436.
<https://doi.org/10.7150/thno.32854>.
10. M. Qin, G. Wei, X. Sun, Circ-UBR5: An exonic circular RNA and novel small nuclear RNA involved in RNA splicing, *Biochemical and Biophysical Research Communications*. 503 (2018) 1027–1034.
<https://doi.org/10.1016/j.bbrc.2018.06.112>.
11. S.A. McClymont, P.W. Hook, A.I. Soto, X. Reed, W.D. Law, S.J. Kerans, E.L. Waite, N.J. Briceno, J.F. Thole, M.G. Heckman, N.N. Diehl, Z.K. Wszolek, C.D. Moore, H. Zhu, J.A. Akiyama, D.E. Dickel, A. Visel, L.A. Pennacchio, O.A. Ross, M.A. Beer, A.S. McCallion, Parkinson-Associated SNCA Enhancer Variants Revealed by Open Chromatin in Mouse Dopamine Neurons, *The American Journal of Human Genetics*. 103 (2018) 874–892.
<https://doi.org/10.1016/j.ajhg.2018.10.018>.
12. G. Barry, J.A. Briggs, D.W. Hwang, S.P. Nayler, P.R.J. Fortuna, N. Jonkhout, F. Datchet, J.L.V. Maag, P. Mestdag, E.M. Singh, L. Avesson, D.C. Kaczorowski, E. Ozturk, N.C. Jones, I. Vetter, L. Arriola-Martinez, J. Hu, G.R. Franco, V.M. Warn, A. Gong, M.E. Dinger, F. Rigo, L. Lipovich, M.J. Morris, T.J. O'Brien, D.S. Lee, J.A. Loeb, S. Blackshaw, J.S. Mattick, E.J. Wolvetang, The long non-coding RNA NEAT1 is responsive to neuronal activity and is associated with hyperexcitability states, *Sci Rep.* 7 (2017) 40127.
<https://doi.org/10.1038/srep40127>.
13. B. Fan, K.-Y. Lu, F.X. Raymond Sutandy, Y.-W. Chen, K. Konan, H. Zhu, C.C. Kao, C.-S. Chen, A Human Proteome Microarray Identifies that the Heterogeneous Nuclear Ribonucleoprotein K (hnRNP K) Recognizes the 5 Terminal Sequence of the Hepatitis C Virus RNA, *Molecular & Cellular Proteomics*. 13 (2014) 84–92.
<https://doi.org/10.1074/mcp.M113.031682>.
14. G. Barry, J.A. Briggs, D.P. Vanichkina, E.M. Poth, N.J. Beveridge, V.S. Ratnu, S.P. Nayler, K. Nones, J. Hu, T.W. Bredy, S. Nakagawa, F. Rigo, R.J. Taft, M.J. Cairns, S. Blackshaw, E.J. Wolvetang, J.S. Mattick, The long non-coding RNA Gomafu is acutely regulated in response to neuronal activation and involved in schizophrenia-associated alternative splicing, *Mol Psychiatry*. 19 (2014) 486–494.
<https://doi.org/10.1038/mp.2013.45>.
15. C.J. Donnelly, P.-W. Zhang, J.T. Pham, A.R. Haeusler, N.A. Mistry, S. Vidsensky, E.L. Daley, E.M. Poth, B. Hoover, D.M. Fines, N. Maragakis, P.J. Tienari, L. Petrucelli, B.J. Traynor, J. Wang, F. Rigo, C.F. Bennett, S. Blackshaw, R. Sattler, J.D. Rothstein, RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention, *Neuron*. 80 (2013) 415–428.
<https://doi.org/10.1016/j.neuron.2013.10.015>.
16. S. Hu, Z. Xie, A. Onishi, X. Yu, L. Jiang, J. Lin, H. Rho, C. Woodard, H. Wang, J.-S. Jeong, S. Long, X. He, H. Wade, S. Blackshaw, J. Qian, H. Zhu, Profiling the Human Protein-DNA Interactome Reveals ERK2 as a Transcriptional Repressor of Interferon Signaling, *Cell*. 139 (2009) 610–622.
<https://doi.org/10.1016/j.cell.2009.08.037>.

8.6 Small Molecule Profiling

1. W.-J. Zhou, H.-L. Yang, J. Mei, K.-K. Chang, H. Lu, Z.-Z. Lai, J.-W. Shi, X.-H. Wang, K. Wu, T. Zhang, J. Wang, J.-S. Sun, J.-F. Ye, D.-J. Li, J.-Y. Zhao, L.-P. Jin, M.-Q. Li, Fructose-1,6-bisphosphate prevents pregnancy loss by inducing decidual COX-2 + macrophage differentiation, *Sci. Adv.* 8 (2022) eabj2488.
<https://doi.org/10.1126/sciadv.abj2488>.
2. M. Zhang, B. Lian, R. Zhang, Y. Guo, J. Zhao, S. He, Y. Bai, N. Wang, Y. Lin, X. Wang, Q. Liu, X. Xu, Emodin Ameliorates Intestinal Dysfunction by Maintaining Intestinal Barrier Integrity and Modulating the Microbiota in Septic Mice, *Mediators of Inflammation*. 2022 (2022) 1–16.
<https://doi.org/10.1155/2022/5026103>.
3. G. Wang, X. Li, N. Li, X. Wang, S. He, W. Li, W. Fan, R. Li, J. Liu, S. Hou, Icaritin alleviates uveitis by targeting peroxiredoxin 3 to modulate retinal microglia M1/M2 phenotypic polarization, *Redox Biology*. 52 (2022) 102297.
<https://doi.org/10.1016/j.redox.2022.102297>.
4. D. Wang, F. Liu, W. Yang, Y. Sun, X. Wang, X. Sui, J. Yang, Q. Wang, W. Song, M. Zhang, Z. Xiao, T. Wang, Y. Wang, Y. Luo, Meldonium Ameliorates Hypoxia-Induced Lung Injury and Oxidative Stress by Regulating Platelet-Type Phosphofructokinase-Mediated Glycolysis, *Front. Pharmacol.* 13 (2022) 863451.
<https://doi.org/10.3389/fphar.2022.863451>.
5. D. Lee, E. Lee, S. Jang, K. Kim, E. Cho, S.-J. Mun, W. Son, H.-I. Jeon, H.K. Kim, Y.J. Jeong, Y. Lee, J.E. Oh, H.H. Yoo, Y. Lee, S.-J. Min, C.-S. Yang, Discovery of Mycobacterium tuberculosis Rv3364c-Derived Small Molecules as Potential Therapeutic Agents to Target SNX9 for Sepsis, *J. Med. Chem.* 65 (2022) 386–408.
<https://doi.org/10.1021/acs.jmedchem.1c01551>.
6. J. Kim, A.Y. Sim, S. Barua, J.Y. Kim, J.E. Lee, Unbound IRF2 to IRF2BP2 mediates KLF4 signaling leading to anti-inflammatory phenotype of microglia, *In Review*, 2022.
<https://doi.org/10.21203/rs.3.rs-2232738/v1>.
7. Q. Guo, Y.-C. Zhang, W. Wang, Y.-Q. Wang, Y. Liu, Z. Yang, M.-M. Zhao, N. Feng, Y.-H. Wang, X.-W. Zhang, H. Yang, T.-T. Liu, L.-Y. Shi, X.-M. Shi, D. Liu, P.-F. Tu, K.-W. Zeng, Deoxyhypusine hydroxylase as a novel pharmacological target for ischemic stroke via inducing a unique post-translational hypusination modification, *Pharmacological Research*. 176 (2022) 106046.
<https://doi.org/10.1016/j.phrs.2021.106046>.
8. C. Gu, Y. Wang, L. Zhang, L. Qiao, S. Sun, M. Shao, X. Tang, P. Ding, C. Tang, Y. Cao, Y. Zhou, M. Guo, R. Wei, N. Li, Y. Xiao, J. Duan, Y. Yang, AHS1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma, *J Exp Clin Cancer Res.* 41 (2022) 11.
<https://doi.org/10.1186/s13046-021-02220-1>.
9. Q. Gao, H. Deng, Z. Yang, Q. Yang, Y. Zhang, X. Yuan, M. Zeng, M. Guo, W. Zeng, X. Jiang, B. Yu, Sodium danshensu attenuates cerebral ischemia–reperfusion injury by targeting AKT1, *Front. Pharmacol.* 13 (2022) 946668.
<https://doi.org/10.3389/fphar.2022.946668>.
10. P. Zhang, W. Tao, C. Lu, L. Fan, Q. Jiang, C. Yang, E. Shang, H. Cheng, C. Che, J. Duan, M. Zhao, Bruceine A induces cell growth inhibition and apoptosis through PFKFB4/GSK3 β signaling in pancreatic cancer, *Pharmacological Research*. 169 (2021) 105658.
<https://doi.org/10.1016/j.phrs.2021.105658>.
11. Y. Xu, C. Liu, X. Han, X. Jia, Y. Li, C. Liu, N. Li, L. Liu, P. Liu, X. Jiang, W. Wang, X. Wang, Y. Li, M. Chen, J. Luo, X. Zuo, J. Han, L. Wang, Y. Du, Y. Xu, J.-D. Jiang, B. Hong, S. Si, E17241 as a Novel ABCA1 (ATP-Binding Cassette Transporter A1) Upregulator Ameliorates Atherosclerosis in Mice, *ATVB*. 41 (2021).
<https://doi.org/10.1161/ATVBAHA.120.314156>.
12. X. Wang, Y. Chen, J. Zhu, Z. Yang, X. Gong, R. Hui, G. Huang, J. Jin, A comprehensive screening method for investigating the potential binding targets of doxorubicin based on protein microarray, *European Journal of Pharmacology*. 896 (2021) 173896.
<https://doi.org/10.1016/j.ejphar.2021.173896>.
13. J. Qian, S. Yin, L. Ye, Z. Wang, S. Shu, Z. Mou, M. Xu, N. Chattipakorn, Z. Liu, G. Liang, An Indole-2-Carboxamide Derivative, LG4, Alleviates Diabetic Kidney Disease Through Inhibiting MAPK-Mediated Inflammatory Responses, *JIR*. Volume 14 (2021) 1633–1645.
<https://doi.org/10.2147/JIR.S308353>.
14. X. Chen, Y. Zhao, W. Luo, S. Chen, F. Lin, X. Zhang, S. Fan, X. Shen, Y. Wang, G. Liang, Celastrol induces ROS-mediated apoptosis via directly targeting peroxiredoxin-2 in gastric cancer cells, *Theranostics*. 10 (2020) 10290–10308.
<https://doi.org/10.7150/thno.46728>.
15. J.M. Coll, Herpesvirus Infection Induces both Specific and Heterologous Antiviral Antibodies in Carp, *Front. Immunol.* 9 (2018) 39.
<https://doi.org/10.3389/fimmu.2018.00039>.

16. C. Azevedo, J. Singh, N. Steck, A. Hofer, F.A. Ruiz, T. Singh, H.J. Jessen, A. Saiardi, Screening a Protein Array with Synthetic Biotinylated Inorganic Polyphosphate To Define the Human PolyP-ome, *ACS Chem. Biol.* 13 (2018) 1958–1963. <https://doi.org/10.1021/acschembio.8b00357>.
17. H. Zhang, L. Yang, J. Ling, D.M. Czajkowsky, J.-F. Wang, X.-W. Zhang, Y.-M. Zhou, F. Ge, M. Yang, Q. Xiong, S.-J. Guo, H.-Y. Le, S.-F. Wu, W. Yan, B. Liu, H. Zhu, Z. Chen, S. Tao, Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic, *Proc. Natl. Acad. Sci. U.S.A.* 112 (2015) 15084–15089. <https://doi.org/10.1073/pnas.1521316112>.
18. Y.P. Kim, D. Park, J.J. Kim, W.-J. Choi, S.H. Lee, S.Y. Lee, S. Kim, J.M. Chung, J. Jeon, B.D. Lee, J.-H. Shin, Y. Lee, H. Cho, J.-M. Lee, H.C. Kang, Effective Therapeutic Approach for Head and Neck Cancer by an Engineered Minibody Targeting the EGFR Receptor, *PLoS ONE*. 9 (2014) e113442. <https://doi.org/10.1371/journal.pone.0113442>.
6. L. Cinquanta, M. Infantino, N. Bizzaro, Detecting Autoantibodies by Multiparametric Assays: Impact on Prevention, Diagnosis, Monitoring, and Personalized Therapy in Autoimmune Diseases, *The Journal of Applied Laboratory Medicine*. 7 (2022) 137–150. <https://doi.org/10.1093/jalm/jfab132>.
7. S. Bérubé, T. Kobayashi, A. Wesolowski, D.E. Norris, I. Ruczinski, W.J. Moss, T.A. Louis, A pre-processing pipeline to quantify, visualize, and reduce technical variation in protein microarray studies, *Proteomics*. 22 (2022) 2100033. <https://doi.org/10.1002/pmic.202100033>.
8. S. Bérubé, T. Kobayashi, A. Wesolowski, D.E. Norris, I. Ruczinski, W.J. Moss, T.A. Louis, A Bayesian Hierarchical Model for Signal Extraction from Protein Microarrays, *Bioinformatics*, 2022. <https://doi.org/10.1101/2022.02.16.480698>.
9. X. Zhang, M. Liu, X. Zhang, Y. Wang, L. Dai, Autoantibodies to tumor-associated antigens in lung cancer diagnosis, in: *Advances in Clinical Chemistry*, Elsevier, 2021: pp. 1–45. <https://doi.org/10.1016/bs.acc.2020.08.005>.

8.7 Reviews

1. N. Yao, J. Pan, X. Chen, P. Li, Y. Li, Z. Wang, T. Yao, L. Qian, D. Yi, Y. Wu, Discovery of potential biomarkers for lung cancer classification based on human proteome microarrays using Stochastic Gradient Boosting approach, *J Cancer Res Clin Oncol.* (2023). <https://doi.org/10.1007/s00432-023-04643-z>.
2. L.H. Carlton, R. McGregor, N.J. Moreland, Human antibody profiling technologies for autoimmune disease, *Immunol Res.* (2023). <https://doi.org/10.1007/s12026-023-09362-8>.
3. N. Bizzaro, L. Cinquanta, R. Tozzoli, Autoantibody profiling in autoimmune rheumatic diseases: How research may translate into clinical practice, in: *Translational Autoimmunity*, Elsevier, 2023: pp. 149–168. <https://doi.org/10.1016/B978-0-323-85831-1.00008-5>.
4. G.M. Aparna, K.K.R. Tetala, Recent Progress in Development and Application of DNA, Protein, Peptide, Glycan, Antibody, and Aptamer Microarrays, *Biomolecules*. 13 (2023) 602. <https://doi.org/10.3390/biom13040602>.
5. H. Qi, J. Xue, D. Lai, A. Li, S. Tao, Current advances in antibody-based serum biomarker studies: From protein microarray to phage display, *Proteomics Clinical Apps*. 16 (2022) 2100098. <https://doi.org/10.1002/prca.202100098>.
10. S. Mukherjee, K. Sundfeldt, C.A.K. Borrebaeck, M.E. Jakobsson, Comprehending the Proteomic Landscape of Ovarian Cancer: A Road to the Discovery of Disease Biomarkers, *Proteomes*. 9 (2021) 25. <https://doi.org/10.3390/proteomes9020025>.
11. T.K. MacLachlan, S. Price, J. Cavagnaro, L. Andrews, D. Blanset, M.E. Cosenza, M. Dempster, E. Galbreath, A.M. Giusti, K.M. Heinz-Taheny, R. Fleurance, E. Sutter, M.W. Leach, Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules – A survey of industry 2008–2019, *Regulatory Toxicology and Pharmacology*. 121 (2021) 104872. <https://doi.org/10.1016/j.yrtph.2021.104872>.
12. S. Li, G. Song, Y. Bai, N. Song, J. Zhao, J. Liu, C. Hu, Applications of Protein Microarrays in Biomarker Discovery for Autoimmune Diseases, *Front. Immunol.* 12 (2021) 645632. <https://doi.org/10.3389/fimmu.2021.645632>.
13. P.V. Belousov, Analysis of the Repertoires of Circulating Autoantibodies' Specificities as a Tool for Identification of the Tumor-Associated Antigens: Current Problems and Solutions, *Biochemistry Moscow*. 86 (2021) 1225–1242. <https://doi.org/10.1134/S0006297921100060>.
14. G.-D. Syu, S.-C. Wang, G. Ma, S. Liu, D. Pearce, A. Prakash, B. Henson, L.-C. Weng, D. Ghosh, P. Ramos, D. Eichinger, I. Pino, X. Dong, J. Xiao, S.

- Wang, N. Tao, K.S. Kim, P.J. Desai, H. Zhu, Development and application of a high-content virion display human GPCR array, *Nat Commun.* 10 (2019) 1997.
<https://doi.org/10.1038/s41467-019-09938-9>.
15. Y. Feng, C.-S. Chen, J. Ho, D. Pearce, S. Hu, B. Wang, P. Desai, K.S. Kim, H. Zhu, High-Throughput Chip Assay for Investigating *Escherichia coli* Interaction with the Blood–Brain Barrier Using Microbial and Human Proteome Microarrays (Dual-Microarray Technology), *Anal. Chem.* 90 (2018) 10958–10966.
<https://doi.org/10.1021/acs.analchem.8b02513>.
16. S. Gupta, K.P. Manubhai, S. Mukherjee, S. Srivastava, Serum Profiling for Identification of Autoantibody Signatures in Diseases Using Protein Microarrays, in: D.W. Greening, R.J. Simpson (Eds.), *Serum/Plasma Proteomics*, Springer New York, New York, NY, 2017: pp. 303–315.
https://doi.org/10.1007/978-1-4939-7057-5_21.
17. S. Liu, H. Zhang, J. Dai, S. Hu, I. Pino, D.J. Eichinger, H. Lyu, H. Zhu, Characterization of monoclonal antibody's binding kinetics using oblique-incidence reflectivity difference approach, *MAbs.* 7 (2015) 110–119.
<https://doi.org/10.4161/19420862.2014.985919>.